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ABSTRACT 
 
Today in the U.S. the narrative of the “bad drug” has become quite a familiar 
account.  There is an ever-growing collection of pharmaceutical products whose safety 
and efficacy has been debunked through the scandalous exposure of violations of 
integrity on the part of researchers, lapses in procedure and judgment on the part of the 
FDA, and reckless profiteering on the part of big pharma.  However, a closer look reveals 
that the oversights and loopholes depicted in the bad drug narrative are not incidental 
failures of an otherwise intact, effective system.  Rather, bad drugs, like good drugs, are a 
product of normal operations of the system; the same processes, actors, and influences 
manifest in both.  The aim of this project is to shed light on these processes, actors, and 
influences at work in drug normalization by interrogating the peculiar case of the drug 
Lupron. Lupron exhibits all of the controversial features of the “bad drug” narrative but 
has remained an endorsed and embraced staple of the infertility industry.  This 
contradiction situates Lupron to expose a number of the contingencies on which drug 
normalization rests more generally.  In order to put forth an explanatory model for drug 
normalization, three such contingencies are described in detail for the case at hand: the 
nature of drug regulation, the structures and value that underpin the medical 
categorization of diseases, and the inextricability of post-medicine from the forces of 
industry.  These contingencies provide some explanatory power for understanding not 
only the retention of Lupron but the ways in which all drugs are produced, validated, and 
perpetuated in a society. 
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INTRODUCTION 
In recent years there has been no shortage of cases wherein the safety and efficacy 
of a drug has been called into serious question.  Some examples include Paxil, the 
antidepressant that may lead to suicidal behavior
1
; Belviq, the binge eating disorder pill 
with marginal efficacy and unanswered questions about its long-term effects
2
; Yaz, the 
birth control pill that has been linked to fatal cardiac and circulatory side effects but not 
yet recalled
3
; Vyvanse, the ADHD drug that recently received FDA approval to be 
marketed for weight loss
4
; Addyi, the “pink Viagra” marketed to improve female sex 
drive
5
; and countless others.   
When the stories of these drugs are told, there are usually a few motifs that recur 
in the typical “bad drug” narrative.  Pharmaceutical companies are cast as recklessly 
amoral profiteers.  Doubt is sometimes cast on the way the FDA executed its discretion.  
                                                 
1
 Dobbs, David. “The Human Cost of a Misleading Drug-Safety Study.” The Atlantic, September 18, 2015. 
http://www.theatlantic.com/health/archive/2015/09/paxil-safety-bmj-depression-suicide/406105/. 
2
 Beyerstein, Lindsay. “Fen-Phen All Over Again?” Slate, July 3, 2012. 
http://www.slate.com/blogs/xx_factor/2012/07/03/fda_approves_new_weight_loss_drug_belviq_is_this_fe
n_phen_all_over_again_.html. 
3
 Deardorff, Julie. “Lawsuits Pile up over Popular Birth Control Pill.” Chicago Tribune, September 13, 
2013. http://articles.chicagotribune.com/2013-09-15/health/ct-met-birth-control-risks-
20130915_1_drospirenone-clots-pills. 
4
 Anderson, L. V. “This Drug for Binge-Eating Disorder May Be Shady. That Doesn’t Mean the Disease 
Isn’t Real.” Slate, February 25, 2015. 
http://www.slate.com/blogs/xx_factor/2015/02/25/binge_eating_disorder_vyvanse_may_not_be_the_right_
treatment_but_the_problem.html. 
5
 Dobbs, David. “What the FDA’s Approval of ‘Pink Viagra’ Tells Us about the Problems with Drug 
Regulation.” Vox. Accessed October 4, 2015. http://www.vox.com/2015/9/18/9333639/female-pink-viagra-
fda-approved. 
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Often there are revelations of fabricated evidence and concealed conflicts of interest.  The 
affected patients are painted as victims duped by the powers that be. 
By now the narrative is a little bit hackneyed.  That is not to say that all of these 
characterizations aren’t at least partly justified.  But they don’t seem to be sufficiently 
nuanced to depict what is really going on.  The narrative is reductionist.  It can get away 
with being reductionist because its focus is on the controversy and the wrong that has 
been committed.  The key actors are usually rendered with clear-cut traits like malevolent 
intent, carelessness, or naivety.  But these characterizations don’t help us understand the 
complexity and fragility of the processes that really explain why questionable drugs are 
able to emerge, become popularly accepted, and achieve commercial success.  All sorts 
of contingencies need to crystallize in order for this to happen.  These crystallizations are 
the product of decisions that are made by individuals, communities, and organizations 
that hold discretionary power at different points in the process.  Furthermore, all of these 
workings take place under a value system that is so basic and implicit to our 
understanding of the world that its significance is often taken for granted in the context of 
science and medicine. 
This is all true not only of “bad drugs” that end up being challenged and/or 
recalled, but also those that turn out to be safe, effective, and beneficial.  Drugs of both 
varieties are products of the same types of processes.  “Bad drugs” are not exceptions to 
the rule, but rather one illustration of it.  Maybe we would like to think of bad drugs as 
sporadic instances of Big Pharma successfully navigating a network of loopholes in an 
otherwise effective system of consumer protection in order to take advantage of 
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vulnerable patients.  But in reality, these are the outcome of normal operations of the 
system.  “Good drugs” traverse the same loopholes, travel the same paths, are driven by 
the same companies, and reach the same patient populations.  The difference is that great 
deal of attention is given to the “bad drugs” because these are the cases where the system 
has ostensibly failed.  There is little incentive to interrogate the operations of that system 
in cases where it produces desirable outcomes, even if those processes are the same ones 
that sometimes lead to undesirable outcomes.  However, because drugs of all varieties 
have parallel explanatory backgrounds, a built understanding of how “bad drugs” come to 
be can help us understand the system at large.   
The case of Lupron is intriguing because its story has all of the scandalous 
characteristics of the “bad drug” narrative, from a striking lack of evidence supporting its 
safety, to widespread accounts of devastating side effects, to devious and illegal business 
practices on the part its manufacturers; and yet, Lupron is not only systematically 
overlooked by regulatory overseers but heartily endorsed by the medical establishment.  
Indeed, Lupron is widely viewed as an indispensable component of standard in vitro 
fertilization (IVF) protocols.  In this way it defies our expectations.  This strange and 
compelling contradiction makes Lupron a good candidate for explanatory deconstruction 
in order to build an understanding of the processes that produce, legitimize, and 
normalize a drug.  This project seeks to interrogate the contradiction given by the case of 
Lupron in order to expose and make sense of some of these processes.   
Interrogating the case Lupron involves asking a series of related questions.  First, 
what forces crystallized in order for Lupron to become recognized as the foremost drug 
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of its type?  Similarly, what led drugs of this type to become critical to IVF?  What 
contingencies explain the acceptance of IVF as an infertility treatment and, more 
generally, for the medical treatment of fertility to be in public demand?  Furthermore, 
what players were active in all of these crystallizations?  What discretion did those 
players exercise?  In what sort of space were they operating and what values were 
implicit in that space?  This line of questioning can, of course, be asked of any drug, 
whether good or bad.  The case of Lupron does not encapsulate all of the complexities 
and dynamics required to explain the emergence and legitimization of every drug.  But 
those processes that are at play in the case of Lupron are relevant to other drugs and their 
exposition can help make sense of drug normalization more generally.  Thus, the goal of 
this analytical project is to point to certain social facts and in doing so articulate an 
explanatory model for how a particular pharmaceutical that complicates the good/bad 
drug dichotomy has become entrenched in a society.  Addressing the aforementioned 
questions about Lupron in particular can help illuminate some of the broader institutional, 
economic, regulatory, and sociocultural configurations that underlie the production and 
consumption of drugs.  Although it is not often acknowledged, all of these configurations 
are based in values.  Things like markets, regulation and policy, and even medicine itself 
are all constructions of human origin and can be traced back to systems of values.  
Though these things are taken as given, in order to truly understand them and their 
outcomes it is important to not treat them this way and instead unpack their underlying 
values.  By taking a hard look at these configurations and extracting their underlying 
values we can better grasp why they exist, how they dictate the actions of institutions and 
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individuals, and the types of relationships between different actors that they promote.  
This is important because in order to be able to say whether something—in this case, the 
structures and processes associated with drug normalization—is working as desired it of 
course must first be known how it works.   
With these aims in mind, the subsequent discussion is organized as follows: in the 
Section I provide background information on the case study.  I describe what the drug 
Lupron is, what it does, and why it is the source of some amount of controversy.  In 
Section II, I offer historical context for the case study.  I do this by providing an overview 
of the history of medical infertility treatment since the discovery of the fertilization event, 
with a special focus on the history of IVF.  I also outline a history of Lupron since its 
entry into the drug market and discuss its confluence with the infertility industry.  In 
Section III, I illustrate a typical scenario of a woman who is pursuing infertility treatment 
at an IVF clinic and the activities and interactions that comprise her experience.  This 
seemingly banal, routine scenario becomes extraordinary when it is colored with the 
knowledge of Lupron as a “bad drug,” and thus paves the way for us to ask on what this 
scenario is contingent.  In Section IV, I proceed to unravel this scenario to examine the 
converging forces and factors that allow it to take place.  These are addressed in several 
sub-sections, including the sociocultural values that underpin reproduction, the privatized 
and technocratic landscape of the infertility industry, and the nature of the regulatory 
environment in which this is embedded.  In Section V, I recap the key messages from my 
previous discussion in the form of set of contingencies that have allowed Lupron to take 
the course that it has taken.  Together these contingencies represent an explanatory model 
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for the normalization of drugs more generally, regardless of whether they are good or 
bad.  
SECTION I: BACKGROUND 
Lupron is the brand-name version of the drug leuprolide acetate. Biochemically, 
leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist.  This means that 
the drug imitates the chemical structure of GnRH, a hormone responsible for triggering 
the production of testosterone and estradiol.  These latter two hormones carry out variety 
of biochemical functions in the reproductive tissues of both men and women.  By 
imitating GnRH Lupron serves to desensitize the body’s GnRH receptors and therefore 
suppress the production of all downstream sex hormones.
6
  Thus, Lupron produces a 
variety of physiological consequences for both the male and female reproductive systems 
and is used in the treatment of disease states related to those systems. 
Lupron was first introduced to the pharmaceutical market in 1985 when it 
received approval from the FDA as a palliative treatment for prostate cancer.  Lupron’s 
ability to suppress testosterone production proved (and continues to be) useful in slowing 
the growth rate of cancerous cells in the prostate. In the years since its introduction, 
Lupron’s medical purview has expanded considerably from its modest beginnings as a 
palliative cancer care drug for men.  Multiple dosage variations of Lupron have been 
introduced and its approved uses have expanded across the sexes and ages to include 
                                                 
6
 Magon, Navneet. “Gonadotropin Releasing Hormone Agonists: Expanding Vistas.” Indian Journal of 
Endocrinology and Metabolism 15, no. 4 (2011): 261–67. doi:10.4103/2230-8210.85575. 
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indications experienced by women, such as endometriosis and pre-operational fibroids, as 
well as precocious puberty in children.   
Today, although Lupron is only officially approved for the aforementioned 
purposes, one of its most prevalent applications is its off-label use in the most popular 
form of infertility treatment: in vitro fertilization (IVF).  In the context of IVF, Lupron 
serves to inhibit female ovulation and force the body into an artificial and temporary 
post-menopausal state.
7
  The subsequent withdrawal of Lupron and introduction of 
additional hormones to stimulate ovulation then encourages the release of many more 
eggs than is typical of a woman’s average cycle.  Such a surge in egg production is seen 
as desirable, especially from the standpoint of the infertility clinician, because the 
ultimate success rate of IVF can be maximized by harvesting as many eggs per cycle as 
possible.  Lupron’s application in IVF continues to expand in parallel to the infertility 
industry, despite the fact that it has not received FDA approval for this purpose.  In fact, 
Lupron is officially contraindicated by the FDA for women who are or may become 
pregnant.
8
  Despite all of this, within the realm of assisted reproductive technology 
Lupron is considered an essential, indispensable component of the IVF process.  Its use is 
at this point deeply entrenched in the norms and practices of the industry.
9
   
                                                 
7
 U.S. Food and Drug Administration. “NDA 019732/S-037 Lupron Depot 7.5 mg (leuprolide acetate for 
depot suspension).” Reference ID: 2888059. 
 
8
 U.S. Food and Drug Administration. “NDA 019010/S-036 Lupron (leuprolide acetate) Injection.” 
Reference ID: 2888059. 
9
 I use the term “entrenched” to indicate Lupron’s largely unquestioned fixedness in IVF protocols.  The 
fact that Lupron was the first drug of its type to enter the market and become widely used has led to this 
state of pervasive entrenchment.  By entering on the ground floor of an industry that is based on 
technocratic and consumer-driven formulations of knowledge, Lupron developed a legacy of effectiveness 
that made it, in some sense, the “safest” choice for women pursuing IVF.  It has become their best bet 
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On one hand, this is not at all surprising.  Lupron is quite effective at 
accomplishing its role in IVF, which has become an increasingly reliable 
biotechnological solution to the problem of infertility.  On the other hand, the 
pervasiveness and importance of Lupron in IVF seems somewhat extraordinary given the 
striking absence of evidence demonstrating its safety in this context as well as lack of 
approval from the FDA.  In these ways and others, the story of Lupron presents some 
interesting revelations how knowledge becomes engrained and how standards are 
developed with regard to health, disease, and treatment.  At the same time, the case 
demonstrates in a broad sense what is required for the successful validation and 
popularization of a health commodity like itself.  The case of Lupron leads us to ask 
certain questions.  In what ways does Lupron defy our expectations about the relationship 
between drug and disease?  How does the case of Lupron unsettle our ideas about the role 
that knowledge plays in health?  What does it reveal about the complex, market-driven 
relationship between pharmaceuticals, their indications, their regulators, and their patient 
consumers?  And what does it show us about the essential ingredients for the production 
and commodification of health solutions?  We can shed light on these questions by telling 
the story of Lupron and interrogating the dynamics that have carried it to proliferation in 
medicine and the infertility industry. 
 
 
                                                                                                                                                 
simply by being the known option.  Although in an official sense very little is known about Lupron, its 
long-standing and wide application lead it to persistently overshadow alternative options about which even 
less is known.  In this way the use of Lupron has crystallized into a norm of IVF practice. 
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SECTION II: THE CONVERGENT HISTORIES OF IVF AND LUPRON 
 In order to understand the nature of Lupron’s role in infertility treatment, it is 
important to know something about its history as a pharmaceutical, as well as the history 
of IVF as a procedure.  Both the drug product Lupron and the technique of IVF existed 
independent of one another before converging to become seamless components of 
today’s most popular assisted reproductive technology.  The story of their convergence 
into a medical solution for infertility provides context for unraveling the dynamics at play 
in this curious case. 
The History of Infertility Treatment and in vitro Fertilization 
The inability to bear children, or “involuntary childlessness,” has been considered 
problematic in one way or another (economically, socially, spiritually, etc.) by many 
societies around the world and across time.  Depending on how these societies primarily 
conceptualized involuntary childlessness, its solutions have varied from adoption to 
religious rites to fashionable therapeutic measures such as sea bathing and consumption 
of dog meat.
10
  A full account of the many historical and cultural approaches to 
involuntary childlessness is beyond the scope of this project; it will suffice to remark that 
the inability to bear children is a status that has been culturally interpreted and 
problematized in many different ways.  In the U.S. today, the dominant interpretation of 
involuntary childlessness is, for the most part, a strictly medical one.  Consequently, it is 
                                                 
10
 Greil, Arthur L. Not yet Pregnant: Infertile Couples in Contemporary America. New Brunswick [N.J.]: 
Rutgers University Press, 1991. 
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this interpretation that will be the focus of the forthcoming historical account of the 
relationship between infertility, IVF, and Lupron. 
Interpretation of involuntary childlessness as the medical condition of “infertility” 
is a relatively recent historical development.  The most basic piece of foundational 
knowledge leading to modern medical infertility treatment can be traced back to the mid-
19
th
 century, when it was recognized that conception results from the fertilization of an 
ovum with a sperm cell.  A physiologically accurate understanding of conception was, 
until then, unprecedented.  This knowledge paved the way for the identification of 
conditions that impeded fertilization as well as the development of medical techniques 
seeking to overcome those conditions. The most popular of these included artificial 
insemination and partial ovarian transplantations, both which were performed with very 
limited success during the early 20
th
 century.  Despite the meager success rates of these 
early infertility treatments, the domain pushed forward, carried partly by the impetus of 
popular demand by women who were involuntarily and unhappily childless.   
The first U.S. infertility clinic was founded by gynecologist John Rock 1926 as 
part of the Free Hospital for Women in Baltimore.  Shortly after came the seminal 
discovery that would come to revolutionize the treatment of infertility: the identification 
of the female sex hormones progesterone and estrogen in 1928 and 1929
11
.  The 
realization that hormones play a critical role in ovulation and pregnancy broadened the 
focus of infertility treatment, which had until this point been largely surgical in its 
approach. Acknowledgment of this biochemical dimension of fertility led to the 
                                                 
11
 “WGBH American Experience . Test Tube Babies | PBS.” American Experience. Accessed September 
20, 2015. http://www.pbs.org/wgbh/americanexperience/features/timeline/babies/. 
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formation of new field known as reproductive endocrinology.  Even today this field 
continues to serve as the primary medical specialization for addressing infertility. 
It wasn’t long before physicians began leveraging endocrinology in the realm of 
childbearing.  In the early 1940s, doctors began prescribing the first synthetic estrogen, 
diethylstilbesterol (DES), to pregnant women.  It was believed that this estrogen analog 
would prevent pregnancy complications and miscarriages, but in fact these alleged 
benefits were unsubstantiated and ultimately false.  It was later discovered that DES 
causes a rare form of vaginal cancer in the children of women who had taken the drug 
while pregnant, and it was eventually recalled completely.
12
  Thus, although 
endocrinology was a rapidly growing field during the early to mid-twentieth century, the 
case of DES suggests that the role played by hormones in pregnancy was still poorly 
understood at this time.  It was not until several decades later that hormones were used in 
the capacity of infertility treatment.  This can be at least partly explained by the persistent 
embrace throughout the 1950s of the misled notion that female infertility was strictly 
rooted in emotional problems.  In the 1960s, however, the development of two particular 
pharmaceuticals demonstrated otherwise.  Clomiphene citrate and human menopausal 
gonadotropin (hMG) were discovered to be effective at regulating the ovulatory cycle and 
thus presented a solution to infertility in cases where irregular ovulation or anovulation 
was the source of the problem.  These two drugs represent the first truly reliable 
                                                 
12
 United States Department of Health and Human Services.  Centers for Disease Control and Prevention. 
“DES History.” 
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pharmaceutical solution for infertility.
13
  Clomiphene citrate and hMGs continue to play a 
major role in IVF to this day. 
While great strides were made in understanding the biochemical dimensions of 
fertility during the early- to mid-twentieth century, surgical avenues of treatment were 
simultaneously (but separately) explored.  Indeed, almost as soon as the mechanism of 
fertilization was discovered in 1878, scientists and physicians began to attempt to fertilize 
a variety of mammals’ ova in vitro and produce embryos.14  In 1934, the in vitro 
fertilization and transplantation of rabbits’ ova was first attempted by U.S. scientist 
Gregory Pincus.  Although Pincus failed in his attempt, the implications of his work 
caused him to be publicly vilified, denied tenure, and dismissed from his position at 
Harvard University.
15
   
Thus, it is clear that from the earliest stages of IVF, the U.S. presented an 
ideological backdrop that was hostile and unreceptive to the technology.  While these 
ethical concerns deterred some scientists (such as the aforementioned Dr. John Rock), 
others continued their quest to achieve mammalian in vitro fertilization outside of the 
approval of the media and oversight bodies
16
.  Over a hundred unsuccessful attempts to 
fertilize human ova were carried out over the course of the mid- to late-1940s, though 
                                                 
13
 Greil, Arthur L. Not yet Pregnant: Infertile Couples in Contemporary America. New Brunswick [N.J.]: 
Rutgers University Press, 1991. 
14
 Bavister, B. D. “Early History of in Vitro Fertilization.” Reproduction 124, no. 2 (August 1, 2002): 181–
96. doi:10.1530/rep.0.1240181. 
15
 “American Experience | The Pill | People & Events: Gregory Pincus.” Accessed September 30, 2015. 
http://www.pbs.org/wgbh/amex/pill/peopleevents/p_pincus.html. 
16
 Biggers, John D. “IVF and Embryo Transfer: Historical Origin and Development.” Reproductive 
BioMedicine Online 25, no. 2 (August 2012): 118–27. doi:10.1016/j.rbmo.2012.04.011. 
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these experiments were performed with no intent to implant and engender pregnancy.  
Only in 1959 was it demonstrated for the first time in a rabbit model that in vitro 
fertilization of an egg and subsequent transplantation of the resulting embryo could lead 
to pregnancy, normal development, and live birth.
17
   
This critical proof of concept demonstrating that the technology really could 
produce children was a major achievement that vitalized the field of IVF during a time 
when the establishment’s ethical objections to reproductive technology were very strong.  
Pope Pius XII had officially condemned IVF in 1949 on the grounds that it violated 
God’s natural order.  In 1954, a court in Illinois ruled that children who were the result of 
artificial insemination by donor sperm were illegitimate in the eyes of the law
18
.  Despite 
these and other condemnations by authorities, demand for IVF remained strong among 
communities of infertile couples, and research and development in the field pressed on. 
In 1968, human ova were successfully fertilized in vitro for the first time by 
doctor Patrick Steptoe and embryologist Robert Edwards.  This achievement was made 
possible in part by the development of laparoscopic surgical technique, which allowed for 
retrieval of fully mature eggs from the ovaries.
19
  Although no attempt was made to 
implant these embryos, this milestone reinforced assisted reproduction and infertility as a 
legitimate and lucrative medical subfield, as evidenced by the fact that the number of 
                                                 
17
 Cohen, Jean, Alan Trounson, Karen Dawson, Howard Jones, Johan Hazekamp, Karl-Gösta Nygren, and 
Lars Hamberger. “The Early Days of IVF Outside the UK.” Human Reproduction Update 11, no. 5 
(September 1, 2005): 439–60. doi:10.1093/humupd/dmi016. 
18
 “WGBH American Experience . Test Tube Babies | PBS.” American Experience. Accessed September 
20, 2015. http://www.pbs.org/wgbh/americanexperience/features/timeline/babies/. 
19
 “WGBH American Experience . Test Tube Babies | PBS.” American Experience. Accessed September 
20, 2015. http://www.pbs.org/wgbh/americanexperience/features/timeline/babies/. 
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physician members of the American Fertility Society increased from 3,000 in 1968 to 
10,000 in 1984.
20
  However, at the same time that support was mounting in the medical 
community, a majority of Americans remained opposed to IVF.
21
   
Even so, the number of infertile couples willing to subject themselves to 
experimental IVF attempts was in no short supply.  In the U.S., the first attempt to 
implant a fertilized embryo into a woman was carried out by doctors William Sweeny 
and Landrum Shettles.  Their patient was Doris Del-Zio who, after several unsuccessful 
reparative surgeries as well as several failed attempts at artificial insemination, was 
offered an opportunity to undergo IVF in 1973.  Del-Zio underwent six months of 
treatment with fertility drugs before her eggs were surgically removed by Sweeny.  
Shettles then fertilized the eggs with sperm from Del-Zio’s husband, unbeknownst to his 
superiors at Columbia-Presbysterian Hospital.  When the chairman of the hospital, 
Raymond Vande Wiele, learned of the IVF attempt through Shettles’ colleagues, he 
immediately terminated the incubation of the embryos, eliminating any possibility of 
implantation and pregnancy for Del-Zio.  Vande Wiele did so on the grounds that 
Shettles’ activities violated federal regulations, put the hospital at risk of losing funding, 
and put the hospital in a position of liability if the IVF attempt ended poorly.  Ironically, 
the Del-Zios ended up suing both the hospital and Vande Wiele anyway for forcibly and 
                                                 
20
 Greil, Arthur L. Not yet Pregnant: Infertile Couples in Contemporary America. New Brunswick [N.J.]: 
Rutgers University Press, 1991. 
 
21
 Cohen, Jean, Alan Trounson, Karen Dawson, Howard Jones, Johan Hazekamp, Karl-Gösta 
Nygren, and Lars Hamberger. “The Early Days of IVF Outside the UK.” Human Reproduction 
Update 11, no. 5 (September 1, 2005): 439–60. doi:10.1093/humupd/dmi016. 
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abruptly putting an end to the attempt
22
.  The controversy was a major stumbling block in 
the course of IVF research in America and set the country back several years in its 
progress.  Ultimately, the first successful IVF attempt was executed in England by 
doctors Edwards and Steptoe, who had been working for ten years on fertilizing a human 
egg in vitro.  An embryo implanted in Lesley Brown became the first of many efforts to 
advance to pregnancy and eventually the much-anticipated live birth of Louise Brown, 
the first “test tube baby,” in 1978. 
It is interesting to note that the first successful human IVF procedures did not 
involve pharmaceuticals in any way.  Although Edwards and Steptoe had attempted to 
couple IVF with fertility drug therapy, their sustained lack of success led them to strip 
down their methods to a purely surgical procedure.
23
  After the successful birth of Louise 
Brown from these surgical methods, Edwards and Steptoe continued to perform IVF in 
the same way, carrying out egg retrievals without any hormonal stimulation of the 
mother.  Their methods carried a 6% pregnancy rate per cycle.
24
  However, the low levels 
of egg retrieval and low pregnancy rate reflected in early IVF led investigators to return 
to an exploration of pharmaceuticals as a way to stimulate increased and predictable egg 
production.  Human menopausal gonadotropins (hMGs), which had been used to 
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modulate ovulation since the 1940s, were the drug of choice for this purpose.  By 1983, 
researchers were reporting a 30% pregnancy rate per cycle as a result of the use of hMGs.  
In 1986, the first hMG drug product, Metrodin, was approved for use in the treatment of 
infertility in women suffering from polycystic ovarian syndrome.
25
  Although hMGs 
greatly increased the success rate of IVF, 1 in 5 cycles stimulated with hMGs failed as a 
result of premature ovulation.
26
  The answer to this problem came in 1984 in the form of 
a variety of drugs known as gonadotropin releasing hormone agonists (GnRH agonist).  
Prior to administering hMGs, a phase of treatment with GnRH agonists was implemented 
in order to place women’s bodies in a state of artificial post-menopause.  Arresting 
women’s regular hormonal pathways effectively prevents premature ovulation up until 
the point when its administration is ceased, causing a deluge of eggs to be produced.  
Integration of GnRH agonists into IVF protocols increased resulting pregnancy success 
rate to as high as 55% as reported by some studies.
27
  The first commercial GnRH agonist 
to be applied in this capacity was Lupron. 
The History of Lupron 
Lupron made its market debut in 1985 as the flagship product of Takeda Abbott 
Pharmaceuticals (TAP), a joint venture between the Japanese company Takeda Chemical 
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Industries Limited and Abbott Laboratories in the U.S.  Lupron’s inaugural indication 
was its use in the palliation of advanced prostate cancer.  For several years thereafter, 
prostate cancer remained the sole approved use of the drug.  Despite the fact that it 
entered the market officially stamped as a palliative cancer drug for men, Lupron began 
converging on the women’s infertility industry quite early on in its lifetime as a drug.  
This convergence is not surprising in light of the fact that GnRH agonists were being 
investigated (but not yet widely used) in the context of IVF years before Lupron even 
entered the drug market.
28
  Driven by its capacity to dramatically increase the number of 
eggs generated in a cycle of IVF, Lupron rapidly pervaded the infertility industry and by 
1989 was considered a virtually indispensable staple of IVF protocols.
29
   
Just as rapidly as Lupron rose in prevalence, so too did tensions arise between 
different stakeholders responsible for validation for the drug.  In 1990 TAP was cited by 
the FDA for having “undertaken a deliberate campaign to promote this product [Lupron] 
for a wide range of unapproved uses,” especially through “a large number of detail 
representative visits to obstetricians and gynecologists.”30  The scandal generated by TAP 
marketing Lupron, a prostate cancer drug, to OB/GYNs was soon resolved, however, 
when Lupron received approval for use in the treatment of endometriosis in 1990.  With 
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the approval of Lupron for an indication related to the female reproductive system, 
suddenly the marketing of the drug to obstetricians and gynecologists a perfectly 
acceptable activity for TAP to undertake.  Lupron was later also approved for the 
treatment of pre-operational uterine fibroids in 1995.  Importantly, with these additional 
approvals, Lupron gained uninhibited access to the realm of women’s healthcare, 
including fertility and reproduction.
 31
  Lupron has also accrued one pediatric 
indication—precocious puberty—for which it was approved in 1993. 
Since its introduction thirty years ago, a wide range of dosages of Lupron have 
been approved and marketed for different purposes.  Presently the array of available 
Lupron products includes depot suspensions for subcutaneous injection ranging in 
concentration from 3.75 mg to 45 mg, as well as several generic formulations of 
leuprolide acetate.
32
  In more recent years, name-brand Lupron has changed proprietary 
hands on several occasions.  In 2008, the TAP joint venture dissolved and Abbott 
laboratories retained the rights to produce and market Lupron.  Three years later, Abbott 
Laboratories began restructuring in order to create a sub-branch of the company (known 
as AbbVie) that would be dedicated to pharmaceutical research.  When the branches 
finalized their split in 2013 AbbVie retained the rights to Lupron.
33
  Through these 
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commercial maneuvers, Lupron has remained the largely unquestioned drug of choice for 
hormonal downregulation in IVF protocols. 
Although there is no universally established regimen for the administration of 
Lupron during IVF cycles, the great majority of cycles today generally adhere to what is 
known as the “long Lupron” protocol.34  In this method, an injection of one of the lower 
available doses of Lupron is self-administered for about 16 consecutive days, the latter 
half of which are coupled with the administration of a follicle stimulating hormone 
product before performing surgical retrieval of eggs.
35
 To date, roughly 5 million children 
have been born to date as a result of IVF, thanks in part to (among other advances) the 
efficiency and optimization of egg production rendered by Lupron.   Further, as IVF 
becomes more popularized and well-accepted, a larger number of babies are produced 
using IVF each passing year
36
 (making up about 1.6% of the total annual births taking 
place in the U.S. as of 2013
37
) and therefore the enormous market for Lupron continues 
to grow.  To give a sense of the magnitude of this market, in 2012 (the most recent year 
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for which data is available) a total of 128,628 cycles of IVF were performed.
38
  If it is 
assumed that a Lupron-based protocol was used in even a mere 80% of these cycles, at an 
average cost of $200 per regimen of the drug this would amount to a total market value of 
approximately $20.6 million.  Thus, Lupron has developed a highly lucrative market that 
promises to expand further with the continued growth of the infertility industry.   
The “Bad Drug” Narrative Takes Shape 
“Scientifically, there are some unanswered questions about the long term consequences 
those drugs might have on women. There are questions about whether they lead to the 
production of unhealthy eggs, and whether they pose a cancer risk to the mother. That’s 
an area that we…hope to examine.”39 – Kathy Hudson 
 
For all the arguable good it has done in enabling the existence of millions of 
human beings, since the early-1990s Lupron has become embroiled in a mounting 
controversy concerning its use in IVF.  Indeed, over the years Lupron has accumulated all 
of the marks of the conventional “bad drug” narrative, not the least of which is the fact 
that Lupron has never been approved by the FDA for use in IVF protocols.  Even more 
outwardly shocking than this is the fact that there have been remarkably few attempts to 
investigate its safety and efficacy in this context.  As of October of 2015 only one clinical 
trial on the safety and efficacy of Lupron in the context of IVF has been performed, 
completed, and reported results, despite the fact that Lupron has now been used to 
facilitate IVF for some 30 years.  This absence of evidence is starkly contrasted to the 
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dozens of clinical trials that have investigated the role of Lupron in the treatment of its 
original introductory indication of prostate cancer.   
In defense of Lupron’s use in IVF protocols, one might note that clinical trials 
were carried out to investigate its safety and efficacy in the treatment of indications 
related to the female reproductive system (i.e., endometriosis and fibroids).  Such a 
demonstration of Lupron’s safety and effectiveness in women for these indications might 
normally provide reassurance that its off-label use by women undergoing IVF is equally 
safe.  However, for several reasons this evidence has done little to temper the controversy 
of Lupron’s use in IVF.  First, the favorable conclusions produced by the clinical trials of 
Lupron in endometriosis and fibroids remain questioned.  For example, one of the 
original (now retracted) clinical trials demonstrating Lupron’s effectiveness in the 
treatment of endometriosis was found to be based on data that was 80% fabricated by the 
principle investigator.
40
  It has been alleged but not confirmed that other trials had similar 
fraudulent bases.  Second, the manner in which Lupron is administered during an IVF 
protocol is quite different from the manner in which it is used to treat endometriosis or 
fibroids.  When being treated for endometriosis or fibroids, women receive one injection 
of Lupron either every month or every three to six months.  Conversely, women 
undergoing the most popular “long Lupron” protocol receive many days of consecutive 
injections, a regimen that is not at all reflective of the dosing for which the drug received 
its approval.  Moreover, many women whose first IVF attempt ends in cancellation or 
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failure to conceive will undergo additional IVF cycles, and thus will undergo cyclical, 
sustained high doses of Lupron over the course of a few months.  This also contradicts 
official recommendations which state that monthly injections of Lupron should be 
undertaken for a maximum of three months in the case of fibroids and six months in the 
case of endometriosis.
41
  For these reasons, Lupron’s place in IVF remains hotly 
contested despite its approval for other women’s health indications. 
In addition to a general lack of data demonstrating Lupron’s safety and efficacy in 
IVF (and perhaps women’s health more generally), there is also a substantial body of 
evidence suggesting that the drug actually has long-term, irreversible negative effects on 
many women’s physiology.  It is now well established that, when used in the context of 
IVF, Lupron is associated with a significantly higher risk of the potentially life-
threatening side effect of ovarian hyperstimulation syndrome (OHSS).
42
  OHSS can be 
brought on during IVF by the violent shift in a woman’s hormones associated with the 
transition from the post-menopausal state induced by Lupron to a state wherein her 
ovaries are pharmaceutically triggered to produce as many eggs as possible.  In other 
cases, Lupron has been linked to a directly opposing effect informally referred to by 
clinicians as “over-suppression.”  Over-suppression occurs when the hormonal 
suppression induced by Lupron is so powerful that egg production is halted even after the 
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addition of hormonal stimulation.
43
  Incidentally, both hyperstimulation and over-
suppression result in a “failure” or “cancellation” of the IVF cycle that brought on the 
condition, making it necessary for the affected woman to start from the beginning if she 
intends to continue pursuing pregnancy via IVF. 
In addition to these clinically well-documented side effects of Lupron in IVF 
protocols, there is a vast corpus of anecdotal reports from patients about permanently 
disabling side effects.  These include such conditions as dramatic bone density loss 
(which the manufacturers of Lupron now admit is irreversible in some cases
44
), thyroid 
dysfunction, joint deterioration, and cancer.   There is a widely echoed claim within the 
post-IVF community that many fertility doctors, as well as the very labeling of the drug 
product itself, do not accurately present these side effects of Lupron to the patient.  
Indeed, even ostensibly impartial sources of information on Lupron contain shrouded 
suggestions about the severity of the potential harms of the drug.  For instance, the 
WebMD page dedicated to Lupron features a peculiar and disconcerting reminder to 
patients in its side effects subsection: “Remember that your doctor has prescribed this 
medication because he or she has judged that the benefit to you is greater than the risk of 
side effects. Many people using this medication do not have serious side effects.”45  That 
such a reminder is deemed necessary is unsettling in itself.  Equally unsettling is the 
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language of the message, indicating that merely “many” (rather than “the majority of” or 
“most”) people who use Lupron do not experience severe side effects.  The reader is led 
to wonder what has led to such a choice of words and whether there is some yet 
undisclosed evidence demonstrating that Lupron’s severe side effects are more common 
than they are portrayed to be.  As these concerning and suspicious revelations about 
Lupron have escalated and yet continually fallen largely on deaf ears, the drug has gained 
notoriety as the alleged subject of a deliberate effort by manufacturers (and a willful 
negligence on the part of regulators) to downplay and hide its negative effects.   
In recent years, former Lupron patients have begun to demand both resolution to 
the controversy and retribution for their suffering.  Countless lawsuits have been filed 
against the makers of Lupron, both by individual plaintiffs as well as large class action 
suits, accusing the company of deliberately concealing its more severe associated health 
risks and bringing it to market on the basis of fallacious or insufficient evidence.
46
  At 
least one of these lawsuits has reached the federal Ninth Circuit Court of Appeals.
47
  
Former Lupron patients have also begun to rally for legislative action, and as of October 
4, 2015, a petition to the U.S. Congress requesting that the side effects of Lupron in 
women be investigated has received 8,807 signatures.
48
  Patients whose health has been 
negatively affected by Lupron have also self-organized into several advocacy groups 
around the drug, the most prominent of which is the National Lupron Victims Network.  
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Patient groups have 
become increasingly 
active in pushing for 
their collective 
concerns to be 
addressed but have 
been thus far 
ineffective at 
generating any action 
from the drug’s 
manufacturers or 
regulators. 
An additional source of the contention about Lupron is the fact that it is not the 
most safe and effective drug of its class.  Other GnRH agonists (mainly nafarelin and 
goserelin, or name-brand Synafel and Zoladex) have been found to be more effective than 
Lupron.  However, even in the face of strong evidence that Lupron is less effective than 
these alternative pharmaceuticals, it has persisted for a remarkably long time as the near 
universal GnRH agonist of choice used in IVF protocols.
49
  This may be partly the result 
of unlawful marking strategies undertaken by its former manufacturer, TAP.  In 2001, the 
U.S. Attorney brought charges against TAP for bribing doctors with medical equipment, 
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Fig 1: An internal TAP memo that was made public by the Oversight 
Hearings of the Commerce Committee as part of the investigation into the 
company’s illegal marking activities of Lupron.   The memo outlines the 
income that would result from doctors prescribing Lupron to various 
numbers of patients. 
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grants, and vacations in exchange for prescribing Lupron as their principal GnRH 
agonist.  Figure 1 represents one example of the profit-based advertising efforts that TAP 
undertook when marketing Lupron to medical practices.  TAP paid $875 million to settle 
these charges of health care fraud, which at the time was the largest health care fraud 
settlement in U.S. history. 
50
  In addition to providing illegal incentives, as early as 1997 
TAP was providing doctors with promotional materials with false and disparaging 
information about their competitor drugs, an activity the company was cited for by the 
FDA on multiple occasions.
51
  Considering the previously cited estimated value of the 
market for Lupron, it is clear that a great deal of return is at stake in the domain of this 
drug.  It is clear why its manufacturers would want to protect (and, to the greatest extent 
possible, even monopolize) the market for GnRH agonists. 
Finally, IVF is not the only controversial off-label use of Lupron that has been 
documented.  Lupron has been explored as treatment for an extraordinarily wide range of 
conditions, from Alzheimer’s disease52 to atherosclerosis53 to premenstrual syndrome.54  
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In addition, within recent years the hormonal suppression effects of the drug have 
generated interest in its potential as a method of chemical castration.  A handful of 
physicians in the U.S. openly prescribe the drug to sex offenders and pedophiles (a 
largely male group) in order to “lower their testosterone, reduce their sex drive, and 
mitigate deviant desires.”55  However, the objectionable dimensions of this use of Lupron 
are dissimilar to that of IVF in that they have little to do with the health and safety of the 
subject receiving the drug and more to do with violations of individual rights.  Another 
even more controversial application of Lupron has been its use in the treatment of 
childhood autism.  Championed by iconic anti-vaccination physician Mark Geier, the 
“Lupron protocol” for autism is widely considered by the scientific and medical 
community to be a case of unsubstantiated pseudoscience.  Although Geier’s medical 
license was revoked in 2011, the Lupron protocol continues to receive attention as a 
legitimate treatment option, albeit to a far more limited extent,
56
 and a patent application 
for use of Lupron to treat autism is still open and under review.
57
  To a certain extent, the 
persistence of the debunked Lupron protocol for autism distantly echoes what is 
demonstrated by the case of Lupron’s role in IVF: that the subject of the “bad drug” 
narrative can endure, contrary to our expectations, in the face of significant discrediting 
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evidence.  To explain how this can possibly be case requires us to disentangle and make 
sense of the various forces at work. 
At a glance, the aforementioned account of Lupron might give this drug the 
outward appearance of being case of scandal, an outlier, and a bad drug that has slipped 
through the cracks.  This is, however, not the case; for while Lupron may have indeed 
slipped through the cracks, it is not an outlier.  What we regard as the cracks through 
which bad drugs slip in the context of the familiar narratives are actually built into the 
workings of the system.  In a sense, all drugs slip through them.  Thus, although Lupron 
does stand to defy our expectations through the degree to which it is entrenched in IVF, it 
only does so because our expectations are based on an incomplete understanding of drug 
normalization.  If we buy into the bad drug narrative and all of its incompleteness, then 
the case of Lupron looks like a case of controversy.  But if we set that narrative aside and 
look deeper then we can see that Lupron is controversial only on its face.  In a much 
more fundamental way, it is not controversial at all and is in fact representative of the 
forces that are responsible for making all drugs.  Lupron stands to help us expose, 
explain, and understand those forces, which will be the undertaking of subsequent 
sections. 
SECTION III: THE TYPICAL SCENARIO 
It is abundantly clear that Lupron’s history mirrors the standard “bad drug” 
narrative in many ways.   At the same time, it presents a challenge to this narrative in that 
no action has been taken to address the problematic dimensions of Lupron.  Revelations 
about evidence of harm have been systematically unaddressed and Lupron continues to 
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be widely endorsed in its controversial applications.  Such a bald defiance of our 
expectations leads us to ask: how this can possibly be?  This simple but weighty question 
will be approached by first illustrating a typical scenario
58
 of a woman who pursues 
infertility treatment in the form of an IVF protocol involving Lupron, then deconstructing 
that scenario to understand its contingencies.  This seemingly ordinary, all too common 
scenario becomes quite extraordinary and worthy of interrogation when it is viewed with 
Lupron’s rather abysmal track record in mind.  We cannot help but ask what forces and 
factors must have converged in order to make it possible for this scenario to take place 
time and time again despite the it is contingent on the use of a classic “bad drug”? 
 
* * * 
 
A woman in her mid-thirties enters an infertility clinic.  This is not her first 
appointment there.  She and her husband have been trying to get pregnant for more than a 
year now with no success.  After being evaluated at this clinic for possible causes of 
infertility, it was concluded that her fallopian tubes are blocked and she cannot become 
pregnant the “natural” way.   She knows that IVF is her and her husband’s last option that 
could allow them to have the child they have always wanted.  By now, most of her 
friends have several children and she feels an increasing anxiety about her own inability 
to get pregnant, especially in light of her age.  She’s acutely aware that the time left on 
her biological clock is running down.  And so, here she is at the clinic.  She chose this 
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particular infertility clinic because, after scouring the internet, she found that its 
advertised success rates for helping women get pregnant were quite high, although 
admittedly only slightly higher than other clinics.  But of course she will opt for the best 
odds she can get, no matter how marginally better, especially when the treatment is so 
costly and not covered by her insurance. 
At today’s appointment she is consulting with her reproductive endocrinologist 
(RE), who has advised her that IVF is her best and probably only option for having a 
child. The RE reiterates the premise of IVF and then explains on a practical level how her 
cycle will work.  First, he says, she will need to undergo several weeks of therapy on a 
variety of drugs in order to get her hormones in order.  Her hormone production will 
initially need to be completely shut down in order to gain control over her reproductive 
system.  This will be achieved with the drug leuprolide acetate, which she will administer 
to herself through a daily injection.  This process of pharmaceutically shutting down her 
hormones, he notes, may come with certain side effects that are typically associated with 
menopause, such as hot flashes or some bone density loss.  She may also experience mild 
bruising around the injection sites.  Then, once her hormones have been shut off, her 
ovarian follicles will be stimulated with a different oral medication, clomiphene citrate, 
which will encourage her ovaries to produce and release eggs.  Finally, she will receive 
one dose of a drug that will trigger all her eggs to mature, and two days later they will be 
harvested laparoscopically for fertilization and growth outside her body. 
The woman is very excited about the prospect of truly beginning her medical 
journey to finally having a baby, but has a few reservations about the cost and the side 
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effects.  The RE suggests that if the medications are too expensive then she might 
consider purchasing them online from an overseas vendor or buying other women’s extra 
doses off Craigslist.  This is, he says, common cost-cutting practice for women pursuing 
IVF on a budget.  In response to her reservations about potential side effects of the drug 
therapy, the RE reassures her that although leuprolide acetate may cause some mild 
discomforts, this step of the process is extraordinarily important for the production of the 
maximum amount of high quality eggs.  After all, the more high quality eggs, the more 
likely she is to end up with a baby.  This reassurance is more than enough to put the 
woman’s mind at ease.  In any case, any pain and discomfort she might undergo is a 
worthy sacrifice in the pursuit of the ultimate goal: a baby of her own. 
 
SECTION IV: UNRAVELING THE SCENARIO 
The scenario illustrated in Section III is made possible by the convergence of countless 
social, cultural, political, economic, and regulatory elements.  Of the various forces on 
which this scenario is contingent, three will be deconstructed and elaborated on in detail.  
Thus, Section IVF is divided into three parts: 
1. The Ethical Tension behind Drug Regulation 
2. (Bio)medicalization of Infertility: The Nature of the Beast 
3. The Infertility Industry: Privatization, Competition, and Technocracy 
It should be kept in mind that the types of relationships and factors described here are not 
unique to Lupron, IVF, and infertility, nor do they represent a comprehensive explanation 
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of the forces at play in the validation and proliferation of drugs and diseases more 
generally.  Rather, these dimensions comprise an incomplete explanatory model of the 
contingencies that contribute to the popularization of individual drugs, both good and 
bad, in a society. 
The Ethical Tension behind Drug Regulation 
Perhaps the most significant source of tension associated with the application of 
Lupron in IVF is best captured by the words of Kathy Hudson, the Deputy Director for 
Science, Outreach and Policy at the National Institutes of Health.  Responding to 
allegations that the safety and long-term effects of assisted reproductive technology 
(especially IVF) are questionable, Hudson commented: 
“A number of practitioners and researchers in this field have said, Hey listen, you 
may say that we need more data, but meanwhile, people are longing for a healthy 
child. Their biological clocks are going off.”59 
 
Hudson’s candid breakdown of these circumstances illuminates an important reality: that 
oversight and regulation is an exercise in managing trade-offs.  The most significant of 
these tradeoffs is between the potential benefit and potential harm of a given medical 
solution.   
Before being introduced to the market, every drug is ostensibly tested with some 
amount of rigor to affirm its safety and efficacy.  On one hand, collection of this evidence 
is intended to prevent potential maleficence that might be brought about by negative 
effects of the drug.  On the other hand, the activities undertaken to collect this evidence 
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inevitably delay (and in some cases, when the evidence thus indicates, permanently 
arrests) the processes of bringing a drug to market.  The potential beneficence that might 
come from the use of a drug in question is therefore postponed by the processes that are 
designed to ensure its safety and efficacy.  Regulatory bodies, namely the FDA, are 
tasked with determining how these two considerations, which are fundamentally at odds 
with one another, are to be balanced.  Moreover, the FDA must not only determine how 
much evidence is needed but also what quality of evidence.  In other words, when clinical 
trials of a drug demonstrate that it carries both positive benefits and negative side effects 
(as is often the case), the FDA must decide what severity and frequency of side effects is 
acceptable when considered in conjunction with the drug’s desirable health effects.  In 
this way, regulators must make decisions about how to balance both the temporal delay 
associated with evidence gathering as well as the negative findings of that evidence 
against the potential beneficence of a drug.  
The standards established for achieving the risk-benefit balance in practice are 
manmade constructions.  Stated so plainly, this point may seem obvious to us but is in 
fact a rarely-acknowledged dimension of regulatory standards.  Regulatory standards are 
the product of ethical deliberations and value-laden decisions about how the 
aforementioned at-odds considerations—preventing harm and permitting benefit—ought 
to be weighed against one another.  In this way, regulatory standards that may appear 
scientifically pristine on their face can actually be traced back to subjective value 
judgments.  This reality often goes unrealized because these standards are invoked 
without any recognition of the values and processes that were used to establish them.  In 
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this sense FDA regulatory standards represent something of a “black box” in the field of 
biomedicine. The box’s esteemed status and its capacity to churn out safe, effective 
medical solutions with some degree of reliability often lead us to take its inner workings 
and underlying assumptions for granted.  However, in some cases—such as that of 
Lupron, as will be further discussed shortly—those workings and assumptions are more 
visible than others and allow us to glimpse the ethical tension at the core of regulation.   
In addition to being the product of value judgments, the details of these regulatory 
standards are, in a certain way, arbitrary.  For example, clinical trial data associated with 
a statistical p value of less than 0.05 is considered conclusively effective
60—but why was 
this figure established as the golden threshold?  Why not a p value of less than 0.04, or 
less than 0.06?  Why must clinical trials of drugs intended to treat chronic illnesses 
proceed for six months and not six-and-a-half or seven?  Of course someone at some 
point in the past decided that this was to be the case.  While those people may have been 
informed by experience, their decisions were ultimately an attempt to quantify previously 
discussed ethical tradeoff.  Thus, even in cases when clear, firm ethical judgments can 
actually be made, packaging those decisions in the form of practical guidelines is at least 
somewhat of an arbitrary act. 
Thus, the FDA’s regulatory standards are, upon close examination, quite pliable 
in nature.  Nonetheless, these regulations are held up as and widely considered to be a 
rigorous gold standard for determining the safety and efficacy of a drug.  Public trust in 
the quality and rigor of the FDA’s standards has consistently been and continues to be 
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very strong.
61
  Recently, however, the pliable nature of these standards has been exposed 
rather unprecedented loosening of the commitment to the agency’s traditional standards 
in certain cases. A well-known instance is the administration of the experimental drug 
ZMapp to a select few Ebola sufferers prior to the drug undergoing human trials.
62
  
Another example is the passage of “right-to-try” bills in multiple states.63 These pieces of 
legislation are designed with the intention of giving patients an opportunity to access 
investigational pharmaceuticals in cases where the patient’s outlook is terminal and his or 
her life expectancy is low.
 64
  Both of these examples are characterized by a shift in the 
relative importance of the chief ethical considerations previously described.  In these 
special cases, ensuring each drug’s safety through evidence-based investigation was 
considered less important than allowing patients to access the potential benefits of the 
drug.  The need of the patient is sufficiently urgent in these situations as to outweigh the 
potential harms of a drug that has not fully negotiated the traditional regulatory hurdles.  
Instances such as these wherein regulatory guidelines are circumstantially breached make 
evident that these standards are, at their core, rooted in value judgments.   
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At this point in our discussion of tradeoffs and value judgments in pharmacy, it is 
appropriate to recall the reminder found on the Wed MD page for Lupron (“Remember 
that your doctor has prescribed this medication because he or she has judged that the 
benefit to you is greater than the risk of side effects”) as an unusually explicit 
acknowledgment of the ethical balancing act underpinning its use.  Indeed, like the 
previously described cases, the use of Lupron in IVF is a case that illuminates the 
interplay of harm and benefit that underlies the approval and use of all drugs.  But what is 
it about the case of Lupron that makes visible these constitutive ethical tradeoffs and 
value judgments?  First, Lupron has something noteworthy in common with drugs that 
have been permitted to sidestep the FDA’s honored standards in the name of beneficence; 
that is, IVF (and, by extension, Lupron) seeks to address an ostensive problem—female 
infertility—that is of an urgent and time-sensitive nature.  It is true that Lupron has not 
met—and perhaps, with further testing, would fail to meet—the FDA’s regulatory 
standards for use in IVF.  But, as Kathy Hudson points out in no unclear terms, calls for 
further testing and a higher standard of evidence have been largely drowned out by the 
ticking of women’s biological clocks telling them that, like terminal cancer patients or 
Ebola victims, their window of time to take advantage of Lupron and IVF is small and 
constantly shrinking.   
However, although the temporal dimension of infertility may be similar to 
conditions like terminal cancer or Ebola, it differs from these cases in a glaring way.  
That is, female infertility is not at all life-threatening, nor is it even life-shortening.  In 
fact, infertility is only harmful insofar as the inability to produce children is harmful.  The 
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manifestations of this harm are not strictly physical, but rather mental, emotional, and 
perhaps psychosomatic.  Hence, whereas in other cases a lower standard of evidence and 
assumption of greater risk might considered ethically acceptable due to the threat of 
impending death, the risks associated with Lupron as used in IVF simply cannot be 
justified under this logic.  Instead, what is at stake in cases of infertility is the 
psychological harm associated with the failure to fulfill implicit and explicit expectations 
of parenthood.  Thus, although today infertility is widely considered to be a medical 
problem, at its most elementary level it is a sociocultural problem.  The landscape of 
infertility is therefore charged with values that inevitably play into the basic risk-benefit 
tradeoff underlying treatments that seek to address it.   
A final note on the topic of evidence, risk, benefit, and regulation is that the 
complex protocols used in IVF today were performed successfully in humans before even 
being attempted in higher animal models.  The first baby conceived via IVF was born in 
1979, but it wasn’t until 1987 that IVF testing began in baboons, with chimpanzees 
following even later.
65
  Many of the techniques used in later-generation IVF have never 
been tested in animals.  This breach of the standard procedures for evaluating safety and 
efficacy is another example of how ethical tradeoffs, although not always visible, are at 
the core of the operations of biomedicine.  Bypassing animal testing and moving straight 
to human experimentation undoubtedly allows this technology to enter the public sphere 
more expediently than if the official tiered testing of animal models had been followed.  
Undoubtedly a larger number of infertile people to date have been able to have children 
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because of this, and so skipping animal testing arguably provided some amount of value-
laden benefit.  However, another force at play which is not a matter of ethics is profit 
motive, which also incentivizes a less thorough testing process.  At what cost these 
compromises have been made remains to be seen.  
(Bio)medicalization of Infertility: the Nature of the Beast 
I have just completed a discussion of the way in which decisions about drug 
regulation are rooted in an ethical tension between the potential harm and potential 
benefit of a drug.  As discussed in the previous section, one point of discretion in 
determining how a drug might be used toward solving particular medical problem lies in 
the question of “how grave is this problem?”  Therefore, decisions about the magnitude 
of a drug’s potential benefit are critically linked to the conceptualization of the condition 
the drug is aiming to treat, i.e., what problem it is aiming to solve.  However, another 
point of discretion is buried in the question of “why do we consider this a (medical) 
problem?”  As is true of the establishment of regulatory standards, someone at some 
point—or, more accurately, many people over a period of time—decided that the 
condition of interest represented a problematic state, and a medical one at that.  In the 
case of Lupron and IVF, it is important to take a closer look at its target condition, 
infertility, and the way that it has come to be construed as a medical problem—or, the 
biomedicalization of infertility. 
Biomedicalization is the next generation of medicalization.  Medicalization theory 
describes the processes by which human statuses come to be construed as medical 
problems and the general expansion of medicine into broader and deeper arenas of human 
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life.  The early champions of medicalization described it as a movement from “badness to 
sickness,” or in other words a trend toward reinvention of social problems in medical 
terms.
66
  Thus, medicalization revealed the reality that medicine has a sociocultural 
dimension and the designation of disease states relies on implicit and explicit 
sociocultural values.  Although such a reality remains true today, medicalization is now 
inadequate to account for the degree of complexity and novel set of dynamics that have 
come to dominate medicine in recent decades.  Thus, the biomedicalization framework 
was proposed to build upon medicalization and make sense of these new developments. 
Biomedicalization describes the body of processes at work in post-modern 
medicine that contribute not only to the shift of human statuses and conditions into the 
purview of medicine but also the sociocultural, economic, institutional forces that are co-
constitutive of the remaking of medicine today.  For example, the framework describes 
such developments as the increasing corporatization of medicine, the commodification of 
health, and a heightened emphasis on self-surveillance of health risks.
67
  These and other 
processes described by biomedicalization are quite relevant to the case of medical 
infertility and its treatments.  Although infertility was initially the product of 
medicalization, it has subsequently been (and continues to be) reshaped by the forces of 
biomedicalization.  For example, while medicalization describes a regime wherein 
doctors are the gatekeepers of medicine for their patient populations, biomedicalization 
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points to the fact that patients are now gathering knowledge in new, varied, and stratified 
ways.  We can see these realities play out in IVF insofar as infertility patients take the 
knowledge production and consumption process surrounding their treatment into their 
own hands.  As patients seek advice and gather expertise from diverse sources (ranging 
from scholarly journal articles to other women’s anecdotal experiences) they not only 
consume but also contribute to the production of popular knowledge on these topics.  All 
of these exchanges are deeply facilitated by internet media.  Thus, doctors no longer 
represent the sole (or even primary) source of medical expertise.  In addition, while 
medicalization describes doctor and patient roles that are based on more traditional 
configurations of providing public good, biomedicalization depicts a state of medicine 
wherein patients act as consumers and doctors act as vendors of products and services.  
Thus, in the era of biomedicalization, doctors and patients are burdened with a different 
and more complex set of rights and responsibilities as compared to the era of 
medicalization, when patient care was less entwined in market enterprise.  This 
configuration is precisely reflected in the roles taken on by the doctors and patients of the 
infertility industry, as will be discussed more thoroughly in the next subsection.  It is for 
these reasons, among others, that biomedicalization is a useful framework to adapt to the 
case of infertility and make sense of its present state of entanglement in medicine. 
Rather than provide a more complete historical account of the processes by which 
infertility has come to be thought of as a medical problem, I will instead provide a brief 
explanation of the values and structures that support this categorization, followed by a 
more detailed account of the effects and outcomes of the biomedicalization of infertility.  
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Tracking these outcomes has important consequences for understanding the current state 
of the infertility industry and its roots in broader trends in biomedicine. 
 
* * * 
 
At the most basic level, designation of a human status or condition as medically 
problematic—i.e., a disease—is founded in the basic principle that pain and suffering are 
undesirable and should be avoided and/or resolved.  However, what counts as pain and 
suffering is mediated by certain sociocultural contingencies.  The role that sociocultural 
construction plays in a disease designation varies in its visibility from case to case.  To 
offer a rather extreme juxtaposition of examples, while Ebola seems straightforwardly 
problematic in that causes intense physical suffering and often death, ADHD is 
considered problematic for in that it decreases the ability to be productive and successful 
by whatever definitions of productivity and success prevail in society.  Clearly, 
socioculturally constructed values are more readily apparent in the latter of these two 
examples as a defined disease state.  In all cases it is worthwhile to examine those values 
on which the disease is founded and assess the weight that they carry in answering the 
question of “why do we consider this a (medical) problem?”  As it so happens, in the case 
of Lupron these values are quite baldly visible and thus the story is easy to read in these 
terms. 
The single most important value at play in the treatment of infertility in the U.S. is 
that of pronatalism, or the importance of having biological children.  This value is not 
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only active in the risk-benefit assessments made by systems and individuals about 
solutions to infertility, but is actually co-constitutive of the very medical 
conceptualization of infertility.  As previously stated, today in the U.S. the inability to 
bear children is firmly considered to reside firmly within the purview of medicine, but 
this categorization is a relatively recent historical development.
68
  The fact that doctors 
today are able to diagnosis of such a thing as “infertility” is the result of the gradual 
medicalization of a fundamentally social condition formerly referred to as “involuntary 
childlessness.”  In order to understand the critical role that values such as pronatalism, 
reproductive autonomy, and others continue to retain in medicalized infertility, an 
account of the sociocultural basis of infertility is warranted. 
As a disease state, infertility is rooted in concepts of deviancy versus normalcy.  
In essence, women who are unable to conceive and/or give birth are assigned a status that 
is “deviant” because it violates sociocultural expectations of childbearing.  Such 
pronatalistic expectations and the importance of childbearing are deeply entrenched in 
American society.
69
  These values have been so pervasive that, for many years, medical 
documentation of infertility was even required in order to submit an infant adoption 
application.
70
  Today, studies show that contemporary Americans continue to think of 
childbearing and parenthood as paramount for a number of reasons.  The most prominent 
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of these include children’s capacity to provide love, stimulation, a kind of immortality,71 
a sense of accomplishment, and, most importantly for the purposes of this discussion, a 
sense of adulthood and social identity.  These last two factors are critically important for 
understanding the manner in which sociocultural expectations underpin the act of having 
children.  American adults report that having children is the single most important life 
event that leads them to feel that they have achieved competent adulthood and that they 
have “grown up” in the eyes of society.72  Thus, biological children undoubtedly 
represent a critical component of the culturally-constructed model American adult. 
The model American adult, however, is a gendered construction.  For women, 
childbearing plays a more central and sweeping role in defining sociocultural identity as 
compared to men,
73
 a status that has been historically perpetuated by cultural and 
religious lore throughout the world.
74
  Therefore, despite the fact that the underlying 
causes of infertility can be attributed to both men and women at equal rates, the 
responsibility for and emotional consequences of infertility are not equally distributed.  
As a result women who are unable to bear children are more heavily stigmatized than 
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men in the same position and report that infertility is a greater relative blow to their 
personal identity and social standing.  Women often believe that infertility prevents them 
from achieving womanhood and fulfilling a role in their life that is critical to their sense 
of self.
75
  In fact, fertility and childbearing are such a significant element of the female 
sociocultural function that women often keep secret the fact that they are pursuing 
fertility treatment so as not to expose their condition and the shame associated with it.
76
   
It is without a doubt that the pressure of pronatalistic societal values has long 
fallen unevenly on the shoulders of women, and thus the harm of infertility is especially 
relevant for them insofar as it manifests in social stigmatization, isolation, identity crisis, 
and psychological distress.  The reallocation of childbearing problems to the medical 
field over the course of the 20
th
 century has done little to change this but rather, according 
to Becker and Nachtigall, has simply served as a way of “managing difference from the 
norm.”77  In other words, medicalization of the inability to bear children has offered a 
way to negotiate the element of social deviancy attached to this condition.  For instance, 
the emergence of infertility as a diagnosis has assigned a sense of evidential legitimacy 
(whether justified or not) to those affected by it by relegating the source of their suffering 
to the biomedical sciences.  However, even so, the legitimacy of infertility as a medical 
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condition today remains largely contingent on the persistence of pronatalistic 
sociocultural values. 
Although the consignment of childbearing problems to medicine has in no way 
altered the pronatalistic foundations of infertility, it has had a variety of other effects.  As 
infertility came to be medicalized and later biomedicalized, the range of decisions that 
individuals and couples are able to make about how to approach the problem has 
seemingly been expanded.  Assisted reproductive technologies and pharmaceutical 
solutions have emerged and become widely normalized.  Thus, a cursory glance at the 
field would lead to the conclusion that women’s reproductive rights have been reaffirmed 
with the availability of these new medical choices.  However, in a different sense the 
relegation of infertility to healthcare has also constricted women’s choices in several 
ways.  These constrictions have created a set of conditions that has allowed IVF and 
Lupron to flourish even in spite of the latter’s notoriety.  It should be kept in mind that 
the impacts of the biomedicalization of infertility described hereafter are also relevant to 
the way in which other diseases are affected as they become ensconced in the operations 
of post-modern medicine. 
The first way in which biomedicalization has altered the landscape of infertility is 
through the provision of biotechnological solutions (most notably IVF) that allow babies 
to be made under previously impossible circumstances.  The availability of these 
solutions has caused neglect of other options for infertile couples such as adoption or 
acceptance of a childless lifestyle.  Notably, the acceptability and popularity of these 
options had been on the rise since the 1970s as a result of the emergence of the feminist 
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movement, which contributed much to the expansion of women’s sociocultural roles 
from their previously narrow childbearing domain and began to temper the prevalence of 
gendered pronatalistic values.  However, more recently some of this progress has been 
backpedaled as the popularization of assisted reproductive technologies such as IVF has 
generated what has been referred to as a “resurgence of pronatalist sentiment” and a 
renewed emphasis on the importance of biological children.
78
 Thus, medicalization has 
reaffirmed ideals that encourage women to try to overcome their infertility rather than 
accepting it or taking other courses. 
Secondly, the women and couples who choose to try to overcome their infertility 
are invited to take a medical approach to tackling this ostensive problem and this, too, 
places restrictions on their choices.  The fact that Western medicine is increasingly 
becoming the primary acceptable manner by which to confront infertility can be linked to 
a broader trend whereby medicine has pervaded human life with increasing broadness 
and depth.  Meanwhile, it is not clear that the Western medicine approach is particularly 
exceptional at the goal of producing babies.  One longitudinal study of infertile couples 
who did and did not seek medical treatment found that “while 41 percent of couples 
treated for infertility subsequently conceived, so did 35 percent of those who had not 
received treatment.”79  If generalizable, these findings indicate that medical treatment 
only marginally improves the odds of overcoming infertility.  In addition, the high 
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success of non-Western methods for overcoming infertility suggests that Western 
medicine cannot be justified as the clearly superior approach.  For example, 
anthropologists have found that traditional Kenyan healers have a 33% success rate at 
resolving infertility problems.
80
  In addition, traditional Chinese herbal medicine has been 
found to be even more effective than Western biomedical approaches with a 60% success 
rate.
81
  And yet, in the U.S. these alternative approaches are almost completely 
overlooked in favor of biomedical technologies.  Moreover, although the number of 
women in the U.S. who seek treatment for infertility overall is decreasing annually, the 
number of women who undergoing IVF continues to rise.  Thus, the availability of IVF 
may be further constricting women’s choices by steering them toward the highest-tech 
(and, incidentally, also most expensive) medical option.
82
  
The confinement of women’s choices about how to approach infertility to the 
scope of medicine also encourages them to evaluate those choices in a particular way.  As 
discussed in the previous sub-section, there is a distinctive logic used in the process of 
assessing risk-benefit tradeoffs in the context Western medicine.  This logic, although 
perhaps presented as objective, is in fact pervaded by gendered sociocultural values 
including the importance of reproductive rights and especially pronatalism.  The latent 
grip of these values often manifests in women’s medical decisions with regard to treating 
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their infertility.  Becker and Nachtigall have reported on the way that risk assessment is 
undertaken in the context of American medicine and how it can lead women to take on 
greater risks as they pursue pregnancy through medical treatment.  Their conclusions 
neatly describe the nature of this phenomenon: 
“[Our] research suggests that once infertility is medically designated as a disease, 
both patients and practitioners pursue a ‘cure’ through a well-delineated pattern of 
medical treatment, despite the risks of such treatment and independent of the 
likelihood of success.  When medical views of risk and responsibility are teamed 
with women’s persistence in the pursuit of a pregnancy, medical treatment may be 
taken to extremes.  Americans consider risk-taking to be their prerogative when 
personal histories reflect strong cultural mandates about norms, values, rights, and 
responsibilities, and these in turn are interpreted as health-related by both 
consumers and health professionals.”83 [emphasis added] 
 
Thus, medicalized infertility is a space where the American cultural constructions of risk 
comes face to face with entrenched, gendered pronatalistic values, and these forces 
together can lead to systemic patterns of hazardous health decisions on the part of women 
pursuing treatment.  All signs point to women taking the iconic duo of “safety and 
efficacy” and throwing the former to the wind in the name of the latter. 
 
Fig 2: A tweet from a woman who was, at the time, undergoing an IVF protocol involving Lupron 
exemplifies the type of risk rationalization that is characteristic of women in this positon.   
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This configuration is certainly at play more specifically in the way that women 
engage with the drug Lupron.  Figure 2 displays one woman’s tweet concerning her use 
of Lupron as she pursues infertility treatment through IVF.  At the time of this posting, 
this woman had been undergoing infertility treatment with no success for a duration of 
nearly two years.  Based on her circumstances and the language she uses in this tweet, it 
is clear that she is tenacious in her willingness to shoulder enormous risks and make 
personal health sacrifices (including gambling with the possibility of brain damage
84
) all 
for the sake of “baby G,” who has not even been conceived.  The message she expresses 
exemplifies the patterns of risk rationalization exhibited by women and couples who are 
faced with medical decisions about their infertile condition and must assess the potential 
harms and benefits of their options. 
This message if similarly evoked by Figure 3, a viral Facebook photo that was 
shared to the page of an infertility clinic by one of its customers who successfully 
conceived and subsequently gave birth to the pictured baby.  The surrounding heart is 
constructed from a fraction of the discarded syringes that were used in the process of the 
mother’s infertility treatment.  The mother underwent five IVF cycles before her 
successful pregnancy was achieved.
85
  The darkly cheerful figure and its caption evokes 
the way in which cultural construction of risk in the U.S. leads women to undertake the 
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Fig 3: a viral Facebook 
photo shows a woman’s 
newborn, conceived via 
IVF, surrounded by 
some of the used 
syringes of the fertility 
drugs (including 
Lupron) that were used 
to conceive her.  The 
caption reads: “Thank 
you to Sher Fertility St. 
Louis and Dr. Dayal 
patient Angela, who 
shows the true 
definition of love that 
went into making this 
gorgeous new baby 
girl.” 
risk and pain associated with IVF as part of their personal mission and perceive the 
intensity of that risk to be a reflection of their resolve in the pursuit of motherhood. 
A final function that has been carried out by the medicalization of infertility lies 
in the reality that modern medicine is an industry.  By taking the involuntary lack of 
children from a social problem (which doesn’t provide opportunities for solutions) to a 
medical problem, the status of infertility gains an economic dimension.  A new space in 
the pharmaceutical, medical, biotechnological market is opened and invites itself to be 
filled with solutions.  The transition from sociocultural deviant to medical patient also 
represents an unavoidable transition from sociocultural deviant to consumer.  Therefore 
the relegation of infertility to the realm of medicine amounts to commodification of 
childbearing and babies.  This is because post-modern medicine is an industry that is 
subject to market logic.  Biomedicalizing infertility has turned offspring into a 
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commodity that can be bought and sold.
86
  The importance of this dimension will be 
expanded upon in more depth throughout the subsequent section. 
The Infertility Industry: Privatization, Competition, and Technocracy 
In recent decades, medicine has been transformed into an ever more industrialized 
and commercialized enterprise.  In this enterprise, health and its derivatives have become 
commodities, the line between providing care and conducting business has been blurred, 
and the patient has been made to assume the additional role of consumer.
87
  These 
dramatic changes to the face of medicine have a profound effect on the mechanisms by 
which drugs are normalized.  Thus, it is important to examine the market space in which 
both producers and consumers are operating and the politico-economic circumstances 
that guide these actors’ discretion as they navigate the market.  Of course these 
circumstances vary from drug to drug. In particular, the case of Lupron and the infertility 
industry is characterized by a dizzying confluence of politico-economic circumstances 
(including privatization, competition, lack of regulation, and others) that make it an ideal 
exemplar to illuminate an array of factors that may play a role in the normalization of 
drugs more generally. 
 
* * * 
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Like many sectors of medicine in the U.S., the treatment of infertility is not so 
much of a field as it is a medical-industrial complex.  It is dominated by private 
institutions and technocratic formulations of authority, and has been widely referred to as 
the “wild west” of the medical world.88  While this extreme characterization might be 
arguable, there is no doubt that the American infertility industry is uniquely unwelcoming 
to regulation and governance.  This attribute of the infertility industry makes perfect 
sense, however, when viewed through a historical lens.  Indeed, separation from the 
establishment was a quality of the industry’s configuration almost from the very moment 
it emerged.  Notably, although today this separation is perpetuated by the actors in the 
industry (who have come to quite like the landscape of the “wild west” and the 
advantages it offers them), it was first brought about as a result of actions on the part of 
the healthcare governance bodies.
89
  During the formative years of medicalized infertility 
and IVF, the U.S. (and to perhaps a lesser extent, the U.K.) was quite hostile to the notion 
of test tube babies and assumed a stance of resounding opposition to research in this 
arena.  Researchers who ignored this opposition and continued to perform work in this 
area were cast out of mainstream institutions.  Although the pioneers of IVF sought 
funding from and use of government institutions they were denied on the basis that their 
work was morally indefensible, resulting in such debacles as the botched Del Zio IVF 
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attempt.
90
  Even after the successful birth of Louise Brown, Edwards and Steptoe hoped 
to continue their work under the NHS, but were rejected on ethical grounds.  Instead, they 
were forced to found a private infertility clinic, as were many physicians and researchers 
in the U.S. who wished to continue work in this field.
91
  Thus has emerged an industry 
that was forged outside of the bounds of mainstream medical institutions and has as a 
result developed into deeply privatized, commercialized, and technocratic domain. 
Today, the infertility industry has a strange relationship with the establishment 
that rejected it for so long.  IVF and other assisted reproductive technologies have 
become far more accepted and at this point are quite normalized in society and rarely 
contested on moral grounds.  The shift in the ethical permissibility of IVF technology is 
also reflected in the fact that it is longer the case that mainstream medical institutions 
want nothing to do with the field.  In fact, the 2010 Nobel Prize in medicine was awarded 
to Robert Edwards, one of the researchers responsible for the world’s first IVF baby, for 
his years of work dedicated to refining the technique.
92
  However, it is now the case that 
the infertility industry has become an establishment in its own right and consistently 
resists attempts of governance bodies to establish standards, guidelines, policies, and 
other regulatory rules for the industry.  IVF procedures at some fertility clinics undergo 
IRB review, but only if these clinics are associated with institutions that receive some 
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form of federal funding.  The great majority of clinics are private and therefore carry out 
procedures and techniques that have not been subject to evaluation of their safety, 
efficacy, or ethicalness by a public oversight body outside of the industry.  Rather, the 
American Society for Reproductive Medicine—the industry’s foremost authority body—
has established its own accreditation program for clinics as well as training and 
certification for practitioners in the field.  Even more subtly, however, the industry space 
is pervaded by implicit set of uncodified norms that define way that infertility medicine is 
practiced and the dynamics between actors play out.  This self-moderated regime has 
resulted in a great deal of methodological freedom for infertility doctors, the clinics they 
work for, and the pharmaceutical and biotech companies that supply their needs.  The 
industry’s freedom and hands-off attitude toward third-party oversight is such that 
potential harms of its medical practices may go unnoticed or unacknowledged, even 
when those practices are routine and well-accepted.   
Infertility specialists are not the only group that may benefit from the “wild west” 
regime of their industry.  Many patients, too, take the free operations of the industry to be 
a natural and expected affirmation of their reproductive autonomy.  Adele Clarke and her 
colleagues describe the nature of the industry aptly, remarking that “Ideals of ownership 
and individualism punctuate reproductive practices and services as reproduction becomes 
another do-it-yourself project enabling us to transform our selves, identities, and social 
lives through consumption.”93  Women and couples seeking infertility treatment value the 
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ability to pursue different options and customize their treatment, even in ways that are 
ethically controversial.  Regulation from outside of the industry would limit the range 
ways that their treatment could play out in practice.  For example, pieces of legislature 
have been proposed that would limit the number of eggs that can be implanted into a 
woman or make financial compensation for egg donation illegal.  However, these 
proposals have been violently contested by physicians who operate in the industry as well 
as its consumers.  Jennifer Lahl, the national director for the Center for Bioethics and 
Culture captured the vehemence of this position in recollecting her experience in one 
legislative effort: “I recall testifying to the Georgia State Senate in 2009…what really 
caught me off guard were the throngs of women who held pictures of their IVF babies, 
accusing me of trying to steal their reproductive rights.”  It is abundantly clear that 
notions of reproductive rights and autonomy play an important role in perpetuating a 
certain regime of self-maintained norms within the infertility industry.  The notion of 
consumer protections is not acknowledged in this space where the dominant paradigm is 
that of consumers’ reproductive rights (including the right to not be protected and to 
undertake risks). 
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Fig 4: A controversial advertisement for 
a contest hosted by a Canadian radio 
station that awarded an infertile couple 
with payment for their IVF treatment. 
At this point it is necessary to address and 
justify the use of the term “consumer” in this 
context; for although the medicalization of 
infertility has certainly led women to assume the 
role of “patient,” the economic configuration of 
the reproductive medicine (and indeed the 
industrial nature of post-modern medicine at 
large) has also led them to take on the role of 
“consumer.”  This is a characterization makes 
many people uncomfortable because it amounts to 
assigning a price to human life, reducing its 
production to a series of transactions, and 
acknowledges the dimension of profit attached to such transactions.  But however 
uncomfortable, there is undoubtedly a certain truth evoked by labeling the patrons of the 
infertility industry as consumers.  On the one hand, the fact that patrons of the infertility 
industry are acting as consumers is quite obvious and not surprising.   However, there are 
important implications attached to a system wherein patients are cast as consumers and 
healthcare practitioners are cast as producers and vendors of goods and services.  In 
particular, the consumer-producer configuration reflects on the responsibilities and 
behaviors of different actors and the dynamics that exist between them.  For example, 
compared to a more traditional doctor-patient configuration of healthcare, the clients of 
the infertility industry are responsible for their choices and are positioned to “shop 
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around” for the product/service that suits them best.  Patrons are not only seeking the 
most suitable treatment in a personal sense but also in a financial sense, and thus are 
executing cost-benefit tradeoff logic—market logic—in a quite literal manner.  This 
arrangement, wherein the healthcare subject is the primary negotiator of decisions who 
interfaces directly with the businesses that provide them, has both produced and been the 
effect of a regime in which the reproductive rights of consumers are considered more 
important than consumer protections.  The infertility clinic, on the other hand, is 
responsible for providing products and services that will meet clients’ expectations (in 
this case, the expectation of having a baby) while at the same time profiting from the 
transaction.  The obligations of infertility clinicians, therefore, are comprised of a variety 
of considerations that complicate physicians’ more traditional commitment to providing a 
public good; for in addition to operating as medical doctors providing a pubic good, they 
are also operating as businesspeople providing a commodity. 
Indeed, today more than ever, babies are a commodity that can be bought and 
sold.  The treatment of infertility through medicine and technology has turned babies into 
a product that results from the convergence of goods and services of various market 
segments, from the pharmaceutical and biotechnological sectors to human services like 
donation and surrogacy.
94
  Sometimes the commodified state of babies and childbearing 
is entirely explicit, such as in the advertisement given in Figure 2 wherein a human infant 
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was held up as the prize for a Canadian radio contest.
95
  Of course the human infant 
featured in the ad was not the prize in itself, but instead the station was offering to pay for 
one “deserving” couple’s infertility treatment.  In this controversial advertisement, the 
commodified nature of babies was very directly acknowledged, even going as far as 
assigning them a cash value of prize money.  However, more often the profit-oriented and 
consumer-driven nature of the infertility industry, although very real, is more subtle and 
not directly acknowledged. 
The ways in which the patrons of the infertility medical-industrial complex 
function as “patients” and “consumers” are not distinct from each other, but are rather 
quite entangled.  We can observe this entanglement of the medical and the commercial 
dimensions of infertility in its very definition, as established by American Society for 
Reproductive Medicine (the nation’s authority organization on reproduction and fertility).  
Despite being a purportedly medical definition, is quite evidently aimed at identifying 
clientele and potential consumers of infertility treatment: 
“Infertility is the result of a disease (an interruption, cessation, or disorder of body 
functions, systems, or organs) of the male or female reproductive tract which 
prevents the conception of a child or the ability to carry a pregnancy to delivery. 
The duration of unprotected intercourse with failure to conceive should be about 
12 months before an infertility evaluation is undertaken (6 months if female 
partner is over 35 years of age), unless medical history, age, or physical findings 
dictate earlier evaluation and treatment.”96 [emphasis added] 
 
We can see that the ASMR’s definition of infertility features two distinct age brackets.  
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What is interesting about this definition is that it differs between these brackets in a way 
that is contrary to what might be expected.  As a woman ages and approaches 
menopause, her ability to conceive lowers as a result of the natural aging of her 
reproductive system, and so pregnancy becomes less likely.  One would think, therefore, 
that an older woman should be permitted a longer amount of time to attempt to achieve 
pregnancy (perhaps 18 months compared to the 12 months given to women under 35) 
before being labeled as definitively infertile and targeted for infertility evaluation.  
However, this is not the case.  Instead, women over 35 are recommended to wait only 6 
months—less time than younger women—before seeking infertility evaluation.  One can 
only assume from this peculiar distinction that the ASMR seeks to define infertility not 
only in terms a woman’s inability or unlikelihood to conceive (as might be expected), but 
also in consideration of the urgency of her seeking treatment based on a her remaining 
childbearing years.  Apparently the concept of the biological clock is built into the very 
definition of infertility.
97
  This is relevant to the infertility industry because its market 
consists only of women whose biological clocks have not yet run completely down.  
Indeed, we can see how this definition would make no sense at all in the absence of 
curative medical technologies like IVF.  However, given the availability of these 
technologies, in the case of women who are on their last leg of reproductive years, it is 
important to draw them into the world of treatment before it’s too late.  The definition of 
infertility supplies this force. 
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The validity of this definition has been called into question for being too inclusive 
and based on erroneous estimate of fertility decline, and therefore designed to designate a 
too-large body of patients.  One study found that 34% of its participants would be 
considered infertile by ASRM’s definition, as they had participated in more than one year 
of unprotected intercourse either with or without the intent to conceive a child.
98
  
Furthermore, the definition’s age brackets have been criticized on the basis that the 
studies identifying the 35 years as the tipping point age of women’s fertility declined are 
based on historical birth records, sometimes from hundreds of years in the past, which are 
not representative of fertility today.  More recent studies have demonstrated that fertility 
decline after age 35 is much less significant than previously advertised.
99
  So, the 
definitionally-designated 35-year warning on women’s biological clocks might be 
unsupported.  What is supported, however, is the fact that IVF is dramatically less 
effective in older women, largely because the pharmaceuticals used in the superovulation 
phase of the procedure have a decreased effect as women age and therefore fewer eggs 
are able to be extracted, fertilized, and transplanted.  Because of this, older women have a 
lower overall pregnancy rate resulting from IVF.
100
  In light of this, would make sense for 
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the industry to maintain an age-tiered definition with a relatively young cutoff that does 
not necessarily reflect age-related fertility decline such that women can be identified not 
before it is too late for them to have a baby, but before it is too late for them to use IVF to 
have that baby. 
The “wild west” character of the infertility industry has had other lasting effects 
on the way that the economics of the industry have developed.  Because highly 
privatized, unregulated, and free-market nature lead the treatments to be extremely 
expensive and the market space to be highly competitive.  The average cost of one IVF 
cycle (including diagnosis, drugs, and surgical procedures) in the U.S. is roughly 
$20,000.
101
  Only a fraction of states mandate any—and typically quite negligible—
insurance coverage of these costs.
102
  These financial realities hold one of the keys to 
understanding how Lupron has come to be considered an indispensable component of 
IVF. 
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As a consequence of the intense market 
competition of the infertility industry, clinics 
have been on a constant quest to increase the 
success rate of their procedures since the 
technology emerged.  The mere 6% pregnancy 
rate reported by Edwards and Steptoe’s initial 
endeavors in the early 1980s had risen to a 
22.3% success rates for all clinics by 1995 (this 
is the year Fertility Clinic Success Rate and 
Certification Act mandated that clinics begin 
keeping statistics).
103
 In 2012, 44.4% of all IVF 
transfers resulted in pregnancies.
104
  Clearly 
great strides have been made in increasing the 
likelihood that IVF will achieve its goal and 
clinics today continue to compete with each 
other for a scant percentage point, giving them 
an advantage over other clinics in an intensely 
competitive industry. 
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Fig 5: an advertisement for the Pacific 
Fertility Center attracts customers with the 
guarantees of a baby “or your money back.” 
 63 
 
Lupron has been a major contributor to the optimization of IVF protocols over the 
years.  Lupron maximizes the efficiency of IVF by helping to induce a woman’s body to 
produce an enormous number of eggs which can be harvested, fertilized in vitro, and 
transplanted for pregnancy.  Therefore, the more eggs, the more likely this process is to 
be successful. A higher number of eggs also reduces the chances that a woman will have 
to undergo a second harvest, as she may be able to freeze some amount of embryos for a 
frozen embryo transfer at a later date if her first IVF attempt fails or if she wants to try 
for another child.  Furthermore, a greater number of eggs means that prospective parents 
can have greater control over the quality of their offspring.  Through technologies such as 
pre-implantation genetic diagnosis, information about embryos debilitating conditions 
and other health statuses can be learned and therefore parents can make the decision to 
pass up those particular embryos for implantation, choosing instead to attempt to become 
pregnant with only the healthiest, most desirable candidate embryos.  All of these factors 
represent incentives for the use of Lupron from the perspective of the infertility client, 
particularly in light of the extreme out-of-pocket costs associated with IVF.  So, too, do 
they represent motivations for the fertility clinician, who can take advantage of Lupron to 
increase the overall success rate of their procedures and thereby draw in customers by 
offering them the best possible chance of having a baby.   
The cost-prohibitive nature of IVF and competition in the industry is captured 
perfectly in Figure 4, an advertisement for the Pacific Fertility Centers that was ran in a 
Houston newspaper.
105
  Advertisements like this one are a testament to the extreme 
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lengths to which clinics are willing to go to attract potential patients.  At this time several 
chains of clinics have adopted full- or partial-refund policies for the procedures they offer 
in an effort to gain a leg up over their competition by simultaneously assuaging potential 
client’s financial worries while also emanating an air of infallible confidence in their 
methods.  However, these policies frequently have strings attached.  Patients often must 
meet certain criteria for these refund plans, with more challenging cases of infertility not 
qualifying for them.  Some plans also do not include the cost of diagnostic tests or drugs, 
which can amount to nearly half of the overall cost of a cycle.  However, even if they are 
in some ways too good to be true, these advertising maneuvers are undertaken on an 
increasingly wide scale as competition in the industry continues to stiffen, and have been 
very well received by infertile couples searching for ways to avoid becoming fraught 
with the crippling costs of infertility treatment. 
 
SECTION V: LESSONS FROM LUPRON 
The normalization of Lupron within the medical community and the public sphere 
is contingent on a set of factors that together produce the configurations and dynamics 
that support the normalization of drugs.  These key factors and their significance are 
summarized as follows: 
 
Key Factor #1: Part of the epistemic basis for the acceptance of drugs is an ethical 
tradeoff between risk and benefit.  To be able to say that a drug is “safe and effective” 
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and therefore approved for public use is simply to say that it has met certain standards 
that were constructed by people.  The decisions to establish those standards were based 
on systems of valuation.  Thus, the FDA’s “safe and effective” isn’t some kind of 
objective, infallible stamp.  It is obviously value-laden and therefore flexible under 
different circumstances where risk and benefit are variably balanced.  The essential 
relationship is that threat of harm and level of risk are directly proportional: the greater 
the threat of harm, the greater the level of acceptable risk.  At an institutional level, the 
fact that this relationship is dependent on circumstances can be observed in cases that 
deviate from FDA standards, such as “right to try” laws and the use of investigational 
Ebola drugs.  Specifically in the case of IVF, regulators may be neglecting the potential 
of Lupron to cause harm because infertility is such a socioculturally-weighty, time-
sensitive condition.  Furthermore, the subjectivity of the risk-benefit tradeoff doesn’t just 
manifest on a institutional level.  Every day physicians and patients evaluate the risk-
benefit tradeoff of drugs and treatments with their own personal discretion.  When doing 
so, especially for certain conditions like infertility, they often draw upon sociocultural 
values.  The incorporation of those values is often not visible in risk-benefit tradeoff 
analysis but is critical to understanding how and why drugs are assigned a certain level of 
potential benefit.  In the case of Lupron, the sociocultural values built into the risk-benefit 
tradeoff are more clearly visible than in other cases, but the same principle demonstrated 
here can be extended to other drugs in order to understand their normalization. 
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Key Factor #2: The biomedicalization of infertility has created the conditions for Lupron 
to flourish by relegating childbearing difficulties to medicine.  The impacts of this 
biomedicalization have served to guide infertile women’s decisions toward the use of 
Lupron.  First, the availability of assisted reproductive technology has created a renewed 
pronatalism in America and a neglect of other options like adoption and a childless 
lifestyle.  Second, women who do choose to try to overcome their infertility are steered 
toward treating it with Western medicine as opposed to taking other approaches that may 
be approximately as likely to help them produce a child.  Third, the way that women and 
couples make decisions about treatment is confined to the logic of risk-benefit assessment 
that is standard in American medicine, which leads women to shoulder more risks in 
order to achieve very value-laden concept of benefit.  Lastly, the increasing 
industrialization of medicine means that the decisions made when undertaking infertility 
treatment are also based on market logic wherein childbearing and babies are 
commodities and the ability to obtain these commodities is reduced to a series of goods 
and services that can be bought and sold. 
The third and fourth points in particular require additional elaboration.  When a 
human status or condition is brought into the purview of medicine, those affected by it 
are invited (perhaps even compelled) to address and resolve that condition with medical 
solutions.  When (bio)medicalization occurs, medicine becomes the dominant 
socioculturally acceptable approach to addressing the condition.  This is in part because 
medicine is equated to science, evidence, and objectivity and therefore society considers 
it unwise, irresponsible, and even crazy to reject such things.  However, the guise of 
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valueless-ness attached to medicine and science can obscure the co-constitutive 
relationship of medico-science and values.  Although (bio)medicalization of a condition 
reshapes public values about how to approach that condition, the fact that the conditions 
is designated as medically problematic can also be traced back to values.  It is important 
to examine the co-production of medicine and values by extracting and interrogate the 
assumptions that were lost when a condition became medicalized and its treatments 
emerged in parallel.  It is clear that these assumptions and values still comprise the basis 
on which individuals approach their treatment and the decisions they make, even when 
they are not explicitly acknowledged, and therefore hold a critical role in explaining how 
and why drugs come to be normalized. 
 
Key Factor #3: The infertility medical-industrial complex is one that eschews regulation 
and oversight, largely as a result of historical factors (the long-standing rejection of IVF 
technology on ethical grounds by the establishment) and patient-consumers notions of 
reproductive rights and autonomy.  This widespread absence of regulation means that 
there is a distinct lack of longitudinal record-keeping that would document health 
consequences for patients after they undergo IVF and treatment with Lupron.  In 
addition, the privatized state of the industry leads to intense competition between 
infertility clinics and systemic lack of insurance coverage leads to extremely high out-of-
pocket costs to patrons of the industry’s services.  These conditions allow Lupron to 
thrive because of the part that it plays in IVF, greatly increasing the number of eggs that 
can be extracted per cycle and thereby increasing pregnancy rate.  Infertility clinics see 
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this as desirable because the ability to advertise high success rates is critical to a clinic’s 
success in such a competitive market.  Consumers see this as desirable because the ability 
to extract more eggs not only increases their chances of a cycle leading to pregnancy and 
decreases the odds of having to undergo a second, very expensive cycle; it also raises the 
possibility of freezing embryos for future transfers if the first round of implantations fails, 
which is a much less expensive option than starting IVF “from scratch.”  Therefore, 
financial conditions and market competition in the industry make Lupron an important (if 
not harmless) component of treatment.  Although not officially endorsed by third-party 
health governance, the infertility industry has become an establishment in its own right 
and now operates with a set of uncodified norms, standards of practice, knowledge 
authorities, and social relations.  It is under this regime that Lupron is embraced by the 
public and endorsed by medicine. 
 
What can be learned more generally from deconstructing the case of Lupron in 
this fashion?  First, the perception that a human status is problematic is a reflection of 
sociocultural values.  When a problematic status comes to be considered medical in 
nature, the regimes of medicine reflect back on societal values and behaviors, changing 
the way in which that condition is approached.  We can see this take hold institutionally 
in the regulation of drugs insofar as the type of risk-benefit analysis conducted by 
oversight bodies inevitably accounts for these values, as we can gather from Kathy 
Hudson’s explanation of how lack of evidence in the realm of ART is balanced against 
the desperation of women whose biological clocks are running down.  We can also 
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observe this co-constitutive relationship of medicine and values in the very way in which 
disease states are defined (as evidenced by the ASRM’s definition of infertility, which is 
counterintuitively reliant on the existence of curative treatments simply to define the 
disease).  Furthermore, zooming in from the institutional level, we see that the placement 
of a condition squarely in the domain of medicine has an impact on individuals’ 
behavioral patterns as well.  In particular, patients engage in a particular variety of risk 
evaluation and conceive of their personal rights and responsibilities differently as 
compared to decision-making outside of the context of medicine.  In the case of 
infertility, gendered pronatalistic values run strongly through these notions of risk and 
responsibility and influence women’s behavior and choices as they seek medical 
treatment.  Furthermore, because medicine today is a commercial industry, the patient 
also acts as a consumer and is thus pursues treatment while being engaged in market 
logic wherein health products and services are considered commodities.  This is 
especially true in the case of the highly privatized infertility industry.  However, while 
“wild west” marketplace for babies appears lawless (and from the point of view of 
oversight, is officially so), its operations are in fact dictated by a system of uncodified 
norms (of which Lupron is one important, entrenched piece), including powerful notions 
of reproductive rights, unofficial standards of practice, and intense competition to acquire 
patients.  The absence of regulation in the infertility industry makes it easy for us to see 
this system of uncodified norms, but even in regulated fields such a system still exists. 
It is of these configuration and dynamics that Lupron has been deemed 
acceptable.  At first glance, in light of its “bad drug” characteristics, the normalization of 
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Lupron doesn’t seem to make sense.  However, when we consider those characteristics in 
their appropriate contexts—socially, cultural, politico-economically, and institutionally—
it becomes clear that the contradiction Lupron appears to present on its face is actually 
not a contradiction at all.  Its normalization in the medical community and public sphere 
follows quite sensibly from the effect of several key factors.  These key factors—
including the value laden metrics by which decisions are made in drug regulation, the co-
production of medicine and sociocultural norms facilitated by biomedicalization, and the 
market structures in which the drug and disease are embedded— represent an explanatory 
illustration of how one drug, Lupron, has become normalized.  That Lupron has persisted 
in spite of itself and has overcome its classically “bad drug” reputation to be widely used 
and accepted is what makes the case a uniquely good candidate for inquiry on this level.  
However, at the same time, Lupron is not at all unique; for although Lupron is quite an 
easy case to read in these terms, the same terms can be applied to cases of other drugs. 
The key factors on which Lupron is contingent that I have described here are, to varying 
degrees, relevant to cases of other drugs as well, whether bad, good, or something in 
between. Thus, these lessons from Lupron are simply one important instance of many 
that are playing out in biomedicine at large today. 
  
 71 
 
BIBLOGRAPHY 
 
“American Experience | The Pill | People & Events: Gregory Pincus.” Accessed 
September 30, 2015. http://www.pbs.org/wgbh/amex/pill/peopleevents/p_pincus.html. 
 
Anderson, L. V. “This Drug for Binge-Eating Disorder May Be Shady. That Doesn’t 
Mean the Disease Isn’t Real.” Slate, February 25, 2015. 
http://www.slate.com/blogs/xx_factor/2015/02/25/binge_eating_disorder_vyvanse_may_
not_be_the_right_treatment_but_the_problem.html. 
 
Associated Press. “Experimental Ebola Drug: Questions and Answers about ZMapp.” 
Accessed September 2, 2015. http://www.cbsnews.com/news/experimental-ebola-drug-
questions-and-answers-about-zmapp/. 
 
Bavister, B. D. “Early History of in Vitro Fertilization.” Reproduction 124, no. 2 (August 
1, 2002): 181–96. doi:10.1530/rep.0.1240181. 
 
Becker, Gay, and Robert D. Nachtigall. “‘Born to Be a Mother’: The Cultural 
Construction of Risk in Infertility Treatment in the U.S.” Social Science & Medicine 39, 
no. 4 (August 1994): 507. doi:doi:10.1016/0277-9536(94)90093-0. 
 
Becker, Gay, and Robert D. Nachtigall. “Eager for Medicalisation: The Social Production 
of Infertility as a Disease.” Sociology of Health & Illness 14, no. 4 (December 1, 1992): 
456–71. doi:10.1111/1467-9566.ep10493093. 
 
Beyerstein, Lindsay. “Fen-Phen All Over Again?” Slate, July 3, 2012. 
http://www.slate.com/blogs/xx_factor/2012/07/03/fda_approves_new_weight_loss_drug_
belviq_is_this_fen_phen_all_over_again_.html. 
 
Biggers, John D. “IVF and Embryo Transfer: Historical Origin and Development.” 
Reproductive BioMedicine Online 25, no. 2 (August 2012): 118–27. 
doi:10.1016/j.rbmo.2012.04.011. 
 
Bowen, RL et al. “A clinical study of lupron depot in the treatment of women with 
Alzheimer's disease: preservation of cognitive function in patients taking an 
acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.” Journal 
of Alzheimer’s Disease 44, no. 2 (2015): 549-560. doi: 10.3233/JAD-141626. 
 
Brian, Kate. “The Amazing Story of IVF: 35 Years and Five Million Babies Later.” The 
Guardian, July 12, 2013, sec. Society. 
http://www.theguardian.com/society/2013/jul/12/story-ivf-five-million-babies. 
 
 72 
 
Cahill, Joe. “Abbott vs. AbbVie: Look Who’s on Top Now.” Crain’s Chicago Business. 
Accessed June 11, 2015. 
http://www.chicagobusiness.com/article/20150204/BLOGS10/150209918/abbott-vs-
abbvie-look-whos-on-top-now. 
 
Centers for Disease Control and Prevention, American Society for Reproductive 
Medicine, Society for Assisted Reproductive Technology. “2012 Assisted Reproductive 
Technology Fertility Clinic Success Rates Report.” U.S. Department of Health and 
Human Services (Atlanta, GA, 2014). 
 
Clarke, Adele E., Laura Mamo, Jennifer Ruth Fosket, Jennifer R. Fishman, and Janet K. 
Shim, eds. Biomedicalization: Technoscience, Health, and Illness in the U.S. 1 edition. 
Durham, NC: Duke University Press Books, 2010. 
 
Cohen, Jean, Alan Trounson, Karen Dawson, Howard Jones, Johan Hazekamp, Karl-
Gösta Nygren, and Lars Hamberger. “The Early Days of IVF Outside the UK.” Human 
Reproduction Update 11, no. 5 (September 1, 2005): 439–60. 
doi:10.1093/humupd/dmi016. 
 
Conrad, Peter, and Joseph W. Schneider. Deviance and Medicalization: From Badness to 
Sickness. Philadelphia: Temple University Press, 1992. 
 
Cousineau, Tara M., and Alice D. Domar. “Psychological Impact of Infertility.” Best 
Practice & Research Clinical Obstetrics & Gynaecology, Psychological Issues in 
Obstetrics and Gynaecology, 21, no. 2 (April 2007): 293–308. 
doi:10.1016/j.bpobgyn.2006.12.003. 
 
Deardorff, Julie. “Lawsuits Pile up over Popular Birth Control Pill.” Chicago Tribune, 
September 13, 2013. http://articles.chicagotribune.com/2013-09-15/health/ct-met-birth-
control-risks-20130915_1_drospirenone-clots-pills. 
 
Dobbs, David. “The Human Cost of a Misleading Drug-Safety Study.” The Atlantic, 
September 18, 2015. http://www.theatlantic.com/health/archive/2015/09/paxil-safety-
bmj-depression-suicide/406105/. 
 
Dobbs, David. “What the FDA’s Approval of ‘Pink Viagra’ Tells Us about the Problems 
with Drug Regulation.” Vox. Accessed October 4, 2015. 
http://www.vox.com/2015/9/18/9333639/female-pink-viagra-fda-approved. 
 
Donchin, Anne. “Feminist Critiques of New Fertility Technologies: Implications for 
Social Policy.” Journal of Medicine and Philosophy 21, no. 5 (October 1, 1996): 475–98. 
doi:10.1093/jmp/21.5.475. 
 
 73 
 
“Drugs@FDA: FDA Approved Drug Products.” Accessed October 4, 2015. 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Ove
rview&DrugName=LUPRON%20DEPOT. 
 
Dunson, David B., Donna D. Baird, and Bernardo Colombo. “Increased Infertility With 
Age in Men and Women:” Obstetrics & Gynecology 103, no. 1 (January 2004): 51–56. 
doi:10.1097/01.AOG.0000100153.24061.45. 
 
Elter, K., and L. R. Nelson. “Use of Third Generation Gonadotropin-Releasing Hormone 
Antagonists in in Vitro Fertilization-Embryo Transfer: A Review.” Obstetrical & 
Gynecological Survey 56, no. 9 (September 2001): 576–88. 
Feather, Kenneth R. Notice of Adverse Findings. Letter. From Food and Drug 
Administration. (accessed June 14. 2015). 
 
Friedman, A. J., and M. D. Hornstein. “Gonadotropin-Releasing Hormone Agonist plus 
Estrogen-Progestin ‘Add-Back’ Therapy for Endometriosis-Related Pelvic Pain.” 
Fertility and Sterility 60, no. 2 (August 1993): 236–41. 
 
“The Future of Research and Regulation for Infertility Treatments.” Popular Science. 
Accessed July 26, 2015. http://www.popsci.com/scitech/article/2003-02/future-research-
and-regulation-infertility-treatments. 
 
Geier, Mark, and David Geier. Methods of treating autism and autism spectrum disorders. 
US20070254314 A1, filed October 30, 2006, and issued November 1, 2007. 
http://www.google.com/patents/US20070254314. 
 
Gholipour, Bahar. “Fewer Women Seeking Help for Infertility.” LiveScience.com. 
Accessed September 25, 2015. http://www.livescience.com/42750-fewer-women-
seeking-help-infertility.html. 
 
Golan, A., R. Ron-El, A. Herman, Z. Weinraub, Y. Soffer, and E. Caspi. “Ovarian 
Hyperstimulation Syndrome Following D-Trp-6 Luteinizing Hormone-Releasing 
Hormone Microcapsules and Menotropin for in Vitro Fertilization.” Fertility and Sterility 
50, no. 6 (December 1988): 912–16. 
 
Greil, Arthur L. Not yet Pregnant: Infertile Couples in Contemporary America. New 
Brunswick [N.J.]: Rutgers University Press, 1991. 
 
Greil, Arthur L., and Julia McQuillan. “‘Trying’ Times: Medicalization, Intent, and 
Ambiguity in the Definition of Infertility.” Medical Anthropology Quarterly 24, no. 2 
(June 2010): 137–56. 
 
 74 
 
Griffiths, Sian. “‘Win a Baby’ Competition Criticised by Fertility Groups.” The 
Guardian, October 7, 2011, sec. World news. 
http://www.theguardian.com/world/2011/oct/07/win-baby-competition-canada-radio. 
 
Groenhout, Ruth E. Connected Lives: Human Nature and an Ethics of Care. Rowman & 
Littlefield, 2004. 
 
Hoffman, Lois Wladis, and Jean Denby Manis. “The Value of Children in the United 
States: A New Approach to the Study of Fertility.” Journal of Marriage and Family 41, 
no. 3 (August 1, 1979): 583–96. doi:10.2307/351628. 
 
“Infertility.” American Society for Reproductive Medicine. 2015. 
 
“Investigation into Lupron Side Effects (Leuprolide Acetate).” Petition2Congress. 
Accessed October 5, 2015. http://www.petition2congress.com/1902/investigation-lupron-
side-effects-leuprolide-acetate/. 
 
Johnston, Josephine, Michael K. Gusmano, and Pasquale Patrizio. “In Search of Real 
Autonomy for Fertility Patients.” Health Economics, Policy and Law 10, no. 03 (July 
2015): 243–50. doi:10.1017/S1744133114000164. 
 
Katz, Russell. “FDA: Evidentiary Standards for Drug Development and Approval.” 
NeuroRx 1, no. 3 (July 2004): 307–16. 
 
Katz, Sydney S., and Selig H. Katz. “An Evaluation of Traditional Therapy for 
Barrenness.” Medical Anthropology Quarterly 1, no. 4 (December 1, 1987): 394–405. 
doi:10.1525/maq.1987.1.4.02a00030. 
 
Kenneth R. Feather. Notice of Adverse Findings. Letter. From Food and Drug 
Administration.  
(accessed June 14. 2015). 
Klein v. Abbott, et al. U.S. Court of Appeals for the Ninth Circuit. No. 11-17250. 
 
Lahl, Jennifer. “The Resistance: Sex, Lies and Greed.” The Center for Bioethics and 
Culture. Accessed October 15, 2015. http://www.cbc-network.org/2010/04/the-
resistance-sex-lies-and-greed/. 
 
Lupron | Dangerous Drug Information & Side Effects.” Accessed August 9, 2015. 
http://www.adrugrecall.com/lupron/lupron.html. 
 
“Lupron Subcutaneous : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing.” 
WebMD. Accessed October 2, 2015. http://www.webmd.com/drugs/2/drug-6888/lupron-
subq/details. 
 
 75 
 
Magon, Navneet. “Gonadotropin Releasing Hormone Agonists: Expanding Vistas.” 
Indian Journal of Endocrinology and Metabolism 15, no. 4 (2011): 261–67. 
doi:10.4103/2230-8210.85575. 
 
Martin, Mary C., Carolyn R. Givens, Eldon D. Schriock, Robert H. Glass, and Pramila V. 
Dandekar. “The Choice of a Gonadotropin-Releasing Hormone Analog Influences 
Outcome of in Vitro Fertilization Treatment.” American Journal of Obstetrics and 
Gynecology 170, no. 6 (June 1994): 1629–34. doi:10.1016/S0002-9378(94)70333-7. 
 
Massy-Beresford, Helen. “What’s next for the World’s 5 Million IVF Babies?” The 
Guardian, November 23, 2014, sec. Society. 
http://www.theguardian.com/society/2014/nov/23/whats-next-for-worlds-5-million-ivf-
babies. 
 
Miall, Charlene E. “The Stigma of Involuntary Childlessness.” Social Problems 33, no. 4 
(April 1, 1986): 268–82. doi:10.2307/800719. 
 
The Nobel Assembly at Karolinsky Institutet. “PRESS RELEASE 2010-10-04 The Nobel 
Assembly at Karolinska Institutet Has Today Decided to Award The Nobel Prize in 
Physiology or Medicine 2010 to Robert G. Edwards for the Development of in Vitro 
Fertilization,” October 4, 2010. 
 
Petersen, Melody. “2 Drug Makers to Pay $875 Million to Settle Fraud Case.” The New 
York Times, October 4, 2001, sec. Business. 
http://www.nytimes.com/2001/10/04/business/2-drug-makers-to-pay-875-million-to-
settle-fraud-case.html. 
 
Porter, R.N, W Smith, I.L Craft, N.A Abdulwahid, and H.S Jacobs. “Induction of 
Ovulation for in-Vitro Fertilisation Using Buserelin and Gonadotropins.” Lancet 2, no. 
8414 (1984): 1284–85. doi:10.1016/S0140-6736(84)92840-X. 
 
Purdy, L. “Women’s Reproductive Autonomy: Medicalisation and beyond.” Journal of 
Medical Ethics 32, no. 5 (May 2006): 287–91. doi:10.1136/jme.2004.013193. 
 
Reinberg, S. “Americans Confused About FDA and Drug Safety.” ABC News, March 24, 
2008. http://abcnews.go.com/Health/Healthday/story?id=4508750&page=1 
 
Ried, Karin, and Keren Stuart. “Efficacy of Traditional Chinese Herbal Medicine in the 
Management of Female Infertility: A Systematic Review.” Complementary Therapies in 
Medicine 19, no. 6 (December 2011): 319–31. doi:10.1016/j.ctim.2011.09.003. 
 
Rothman, Kenneth J., Lauren A. Wise, Henrik T. Sørensen, Anders H. Riis, Ellen M. 
Mikkelsen, and Elizabeth E. Hatch. “Volitional Determinants and Age-Related Decline in 
 76 
 
Fecundability: A General Population Prospective Cohort Study in Denmark.” Fertility 
and Sterility 99, no. 7 (June 1, 2013): 1958–64. doi:10.1016/j.fertnstert.2013.02.040. 
 
Rubinow, David R., and Peter J. Schmidt. “Gonadal Steroid Regulation of Mood: The 
Lessons of Premenstrual Syndrome.” Frontiers in Neuroendocrinology 27, no. 2 (July 
2006): 210–16. doi:10.1016/j.yfrne.2006.02.003. 
 
Sherbahn, Richard. “In Vitro Fertiliation, IVF – the Process and Procedures.” Advanced 
Fertility Center of Chicago. Accessed October 6, 2015. 
http://www.advancedfertility.com/ivf.htm. 
 
Singer, Alison. “Complementary and Alternative Treatments for Autism Part 2: 
Identifying and Avoiding Non-Evidence-Based Treatments.” AMA Journal of Ethics 17, 
no. 4 (April 1, 2015): 375. doi:10.1001/journalofethics.2015.17.4.sect2-1504. 
 
Singer, Alison. “Complementary and Alternative Treatments for Autism Part 2: 
Identifying and Avoiding Non-Evidence-Based Treatments.” AMA Journal of Ethics 17, 
no. 4 (April 1, 2015): 375. doi:10.1001/journalofethics.2015.17.4.sect2-1504. 
 
Slater, Eve E. “Today’s FDA.” New England Journal of Medicine 352, no. 3 (January 20, 
2005): 293–97. doi:10.1056/NEJMsb042278. 
 
Spar, Debora L. The Baby Business: How Money, Science, and Politics Drive the 
Commerce of Conception. 1 edition. Boston: Harvard Business Review Press, 2006. 
 
Spar, Deborah L. “Making Laws About Making Babies: Fertility Industry Is a Wild 
West.” The New York Times. Accessed October 14, 2015. 
http://www.nytimes.com/roomfordebate/2011/09/13/making-laws-about-making-
babies/fertility-industry-is-a-wild-west. 
 
Szalavitz, Maia. “Q&A: What Works in Sex-Offender Treatment.” Time. Accessed 
August 17, 2015. http://healthland.time.com/2013/06/10/qa-what-works-in-sex-offender-
treatment/. 
 
Twenge, Jean. “How Long Can You Wait to Have a Baby?” The Atlantic, August 2013. 
http://www.theatlantic.com/magazine/archive/2013/07/how-long-can-you-wait-to-have-a-
baby/309374/?utm_source=SFFB. 
 
Uffalussy, Jennifer Gerson. “The Cost of IVF: 4 Things I Learned While Battling 
Infertility.” Forbes. Accessed October 17, 2015. 
http://www.forbes.com/sites/learnvest/2014/02/06/the-cost-of-ivf-4-things-i-learned-
while-battling-infertility/. 
 
 77 
 
U.S. Congress, Senate, Committee on Commerce, Science, and Transportation, Cloning: 
A Risk to Women?: Hearing before the Subcommittee on Science, Technology, and 
Space. 108
th
 Cong., 1
st
 sess., 2003. 
 
U.S. Department of Health and Human Services.  Centers for Disease Control and 
Prevention. “DES History.” 
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Orange 
Book: Approved Drug Products with Therapeutic Equivalence Evaluations. 
 
U.S. Food and Drug Administration. LUPRON DEPOT® 3.75 mg Label. Reference ID: 
3398735.  
 
U.S. Food and Drug Administration. “NDA 019732/S-037 Lupron Depot 7.5 mg 
(leuprolide acetate for depot suspension).” Reference ID: 2888059. 
 
U.S. Food and Drug Administration. Letter to TAP from the Division of Drug Marketing, 
Advertising and Communications. May 29, 1997. 
 
U.S. Food and Drug Administration. “NDA 019010/S-036 Lupron (leuprolide acetate) 
Injection.” Reference ID: 2888059. 
 
Wang, Jeff, and Mark V Sauer. “In Vitro Fertilization (IVF): A Review of 3 Decades of 
Clinical Innovation and Technological Advancement.” Therapeutics and Clinical Risk 
Management 2, no. 4 (December 2006): 355–64. 
 
Weisman, Kenneth M., and Michael Goldberg. Therapeutic uses of leuprolide acetate. 
US6099851 A, filed June 2, 1998, and issued August 8, 2000. 
http://www.google.com/patents/US6099851. 
 
“WGBH American Experience . Test Tube Babies | PBS.” American Experience. 
Accessed September 20, 2015. 
http://www.pbs.org/wgbh/americanexperience/features/timeline/babies/. 
 
“WGBH American Experience . Test Tube Babies: First U.S. Test Tube Baby Attempt | 
PBS.” American Experience. Accessed October 1, 2015. 
http://www.pbs.org/wgbh/americanexperience/features/general-article/babies-first-us-
attempt/. 
 
“Why Is This Baby Surrounded by Syringes?” TODAY.com, October 9, 2015. 
http://www.today.com/parents/moms-photo-ivf-baby-surrounded-syringes-inspires-
potential-parents-t49276. 
 
 78 
 
Winter, Catherine. “The Infertility Race: Competing for Customers.” American Public 
Media, February 5, 1998. 
http://americanradioworks.publicradio.org/features/fertility_race/part3/section2.shtml. 
 
Zettler PJ, and Greely HT. “The Strange Allure of State ‘right-to-Try’ Laws.” JAMA 
Internal Medicine 174, no. 12 (December 1, 2014): 1885–86. 
doi:10.1001/jamainternmed.2014.5767. 
